<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biomed Res</journal-id><journal-id journal-id-type="iso-abbrev">J Biomed Res</journal-id><journal-id journal-id-type="publisher-id">JBR</journal-id><journal-title-group><journal-title>Journal of Biomedical Research</journal-title></journal-title-group><issn pub-type="ppub">1674-8301</issn><issn pub-type="epub">2352-4685</issn><publisher><publisher-name>Editorial Department of Journal of Biomedical Research</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27533936</article-id><article-id pub-id-type="pmc">4946318</article-id><article-id pub-id-type="publisher-id">jbr-30-04-272</article-id><article-id pub-id-type="doi">10.7555/JBR.30.20150058</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis <italic>in vivo</italic></article-title><alt-title alt-title-type="running-head">Targeting lysophosphatidate signaling</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Benesch</surname><given-names>Matthew G.K.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Xiaoyun</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Venkatraman</surname><given-names>Ganesh</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Bekele</surname><given-names>Raie T.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Brindley</surname><given-names>David N.</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"><sup>&#x02709;</sup></xref></contrib><aff id="aff1"><institution>Signal Transduction Research Group, Department of Biochemistry, University of Alberta</institution>, <addr-line>T6G 2S2</addr-line>, <country>Canada</country>.</aff></contrib-group><author-notes><corresp id="cor1"><label><sup>&#x02709;</sup>&#x0200b;</label>Corresponding author: Dr. David Brindley, 357 Heritage Medical Research Centre, Department of Biochemistry, University of Alberta, Edmonton, Alberta, T6G 2S2, Canada, Tel/Fax: 780-492-2078/780-492-3383; E-mail: <email>david.brindley@ualberta.ca</email>.</corresp><fn fn-type="conflict"><p>CLC number: R589.2, Document code: A</p></fn><fn fn-type="conflict"><p>The authors reported no conflict of interests.</p></fn></author-notes><pub-date pub-type="ppub"><month>7</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>28</day><month>8</month><year>2015</year></pub-date><volume>30</volume><issue>4</issue><fpage>272</fpage><lpage>284</lpage><history><date date-type="received"><day>11</day><month>4</month><year>2015</year></date><date date-type="rev-recd"><day>12</day><month>5</month><year>2015</year></date><date date-type="accepted"><day>20</day><month>5</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2016 by the Journal of Biomedical Research. All rights reserved.</copyright-statement><copyright-year>2016</copyright-year></permissions><abstract><title>Abstract</title><p>Extracellular lysophosphatidate (LPA) is a potent bioactive lipid that signals through six G-protein-coupled receptors. This signaling is required for embryogenesis, tissue repair and remodeling processes. LPA is produced from circulating lysophosphatidylcholine by autotaxin (ATX), and is degraded outside cells by a family of three enzymes called the lipid phosphate phosphatases (LPPs). In many pathological conditions, particularly in cancers, LPA concentrations are increased due to high ATX expression and low LPP activity. In cancers, LPA signaling drives tumor growth, angiogenesis, metastasis, resistance to chemotherapy and decreased efficacy of radiotherapy. Hence, targeting the ATX-LPA-LPP axis is an attractive strategy for introducing novel adjuvant therapeutic options. In this review, we will summarize current progress in targeting the ATX-LPA-LPP axis with inhibitors of autotaxin activity, LPA receptor antagonists, LPA monoclonal antibodies, and increasing low LPP expression. Some of these agents are already in clinical trials and have applications beyond cancer, including chronic inflammatory diseases.</p></abstract><kwd-group><title>Keywords:</title><kwd>cancer</kwd><kwd>chronic inflammation</kwd><kwd>cytokines</kwd><kwd>monoclonal antibodies</kwd><kwd>wound repair</kwd></kwd-group><counts><fig-count count="1"/><table-count count="1"/><ref-count count="152"/><page-count count="13"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>As the simplest phospholipid, lysophosphatidate (LPA) is by no means a simple biological molecule. Extracellular LPA, via signaling through at least six G-protein-coupled receptors, mediates a plethora of physiological and pathological processes including embryogenesis, wound healing, chronic inflammatory diseases, and cancer progression and therapy resistance. LPA has an ester-linked fatty acid at the <italic>sn</italic>-1 or <italic>sn-2</italic> position of the glycerol backbone and a hydroxyl group at the other position, and a phosphate head group at the <italic>sn</italic>-3 position (<xref ref-type="fig" rid="f01"><bold><italic>Fig. 1</italic></bold></xref>). Normally, LPA concentrations in plasma are about 100 nmol/L and this LPA is bound to albumin<sup>[<xref rid="b1" ref-type="bibr">1</xref>-<xref rid="b2" ref-type="bibr">2</xref>]</sup>. LPA can rise to about 1 &#x003bc;mol/L in serum as a result of platelet activation<sup>[<xref rid="b3" ref-type="bibr">3</xref>-<xref rid="b5" ref-type="bibr">5</xref>]</sup>. The majority of extracellular LPA is generated from unsaturated and polyunsaturated lysophosphatidylcholine (LPC) by the lysophospholipase D activity (lysoPLD) of autotaxin (ATX), which hydrolyzes choline from the phosphate head group (<xref ref-type="fig" rid="f01"><bold><italic>Fig. 1</italic></bold></xref>). LPC is the most abundant phospholipid in human plasma where it reaches concentrations of greater than 200 &#x003bc;mol/L<sup>[<xref rid="b6" ref-type="bibr">6</xref>-<xref rid="b7" ref-type="bibr">7</xref>]</sup>. Historically, LPC was believed to be a bioactive molecule. However, more recent work has shown that ATX inhibition blocks the stimulatory effects of LPC on cell migration and survival<sup>[<xref rid="b8" ref-type="bibr">8</xref>-<xref rid="b9" ref-type="bibr">9</xref>]</sup>, demonstrating that the biological actions of LPC are mediated through LPA <italic>via</italic> ATX activity. LPA signaling is terminated by its hydrolysis to inorganic phosphate and monoacylglycerol (MAG) by catalytic activity of three related proteins called the lipid phosphate phosphatases (LPP1-3) (<xref ref-type="fig" rid="f01"><bold><italic>Fig. 1</italic></bold></xref>)<sup>[<xref rid="b10" ref-type="bibr">10</xref>]</sup>. These enzymes were originally characterized by our group as type 2 phosphatidate phosphatases because of their insensitivity to inhibition by N-ethylmaleimide and lack of Mg<sup>2+</sup>- requirement<sup>[<xref rid="b11" ref-type="bibr">11</xref>]</sup>. However, it became evident that they also hydrolyze a wide variety of lipid phosphates including LPA and sphingosine 1-phosphate (S1P) and so they were renamed LPPs<sup>[<xref rid="b12" ref-type="bibr">12</xref>]</sup>. All three LPPs are integral membrane proteins containing six transmembrane helices with the C- and N-termini facing the cytosolic side of the plasma membrane<sup>[<xref rid="b13" ref-type="bibr">13</xref>]</sup>. At the plasma membrane, the catalytic site of the LPPs faces the extracellular environment, enabling them to access and hydrolyze extracellular LPA and other phospholipids<sup>[<xref rid="b10" ref-type="bibr">10</xref>,<xref rid="b13" ref-type="bibr">13</xref>]</sup>.</p><fig id="f01" position="float"><label>Fig. 1</label><caption><title>Overview of the ATX-LPA-LPP axis and points of therapeutic intervention within the axis.</title><p>Extracellular LPA is generated from LPC by the enzymatic lysophospholipase D activity of ATX. LPA can signal through at least 6 G-protein-coupled receptors to mediate both physiological and pathological processes. Extracellular LPA is degraded by the ecto-activity of a family of three enzymes called the LPPs, which hydrolyzes the phosphate head group from LPA to produce MAG. LPPs expressed on the membranes of cellular organelles can also block LPA signaling downstream of receptor activation by endo-LPP activity. LPA signaling can be disrupted by blocking LPA production through ATX activity inhibition, treatment with monoclonal antibodies against LPA, blocking LPA binding to LPA receptors through LPA receptor antagonists, and by increasing expression of LPP<sub>1/3</sub>.</p></caption><graphic xlink:href="jbr-30-04-272-g001"/></fig><p>The prototypical pathology associated with ATX-LPA-LPP axis is best illustrated in cancer. ATX protein expression is increased leading to higher LPA levels in many different tumors. Cancer cells also have increased expression of LPA receptors on their cell surface compared to normal and benign cells, and downregulated expression of LPPs<sup>[<xref rid="b7" ref-type="bibr">7</xref>,<xref rid="b14" ref-type="bibr">14</xref>]</sup>. Thus, a triad of increased LPA production by ATX, increased response to LPA by increased LPA receptor expression and decreased LPP activity to degrade LPA on the cell surface creates the perfect storm for cancer cell proliferation, migration, metastasis and therapy resistance<sup>[<xref rid="b7" ref-type="bibr">7</xref>,<xref rid="b10" ref-type="bibr">10</xref>,<xref rid="b14" ref-type="bibr">14</xref>-<xref rid="b15" ref-type="bibr">15</xref>]</sup>. Other inflammatory diseases including asthma, rheumatoid arthritis, lung and liver fibrosis, and inflammatory bowel diseases are also distinguished from normal physiology by increased ATX/LPA signaling. Hence, the importance of studying LPA signaling within the ATX-LPA-LPP axis is now gaining more recognition<sup>[<xref rid="b16" ref-type="bibr">16</xref>-<xref rid="b17" ref-type="bibr">17</xref>]</sup>. In this review, we will summarize current knowledge of the ATX-LPA-LPP axis in pathology and describe the approaches being taken to target this axis to improve therapeutic interventions.</p></sec><sec id="s2"><title>Overview of the ATX-LPA-LPP axis</title><sec id="s2a"><title>ATX - The predominant producer of extracellular LPA</title><p>Enzymatic generation of LPA in plasma by lysoPLD activity was first described in 1986<sup>[<xref rid="b18" ref-type="bibr">18</xref>]</sup>. ATX is a 125-kDa secreted glycoprotein that was first isolated in 1992 from A2058 melanoma cells and described as an &#x0201c;autocrine motility factor&#x0201d;<sup>[<xref rid="b19" ref-type="bibr">19</xref>]</sup>. At the time, its enzymatic activity and homology to other growth or motility factors were unknown. Two years later, sequencing the cDNA clone of ATX showed that it had significant homology to the plasma cell glycoprotein-1 (PC-1)<sup>[<xref rid="b20" ref-type="bibr">20</xref>]</sup>, which was known to have nucleotide pyrophosphatase and phosphodiesterase (NPP) activity<sup>[<xref rid="b21" ref-type="bibr">21</xref>-<xref rid="b22" ref-type="bibr">22</xref>]</sup>. PC-1 was later named NPP1 and ATX as NPP2, the first two members of a family of seven enzymes that hydrolyze phosphodiester and pyrophosphate bonds to remove phosphates from ADP and ATP<sup>[<xref rid="b6" ref-type="bibr">6</xref>]</sup>. As a secreted enzyme, NPP2 was later referred to as ecto-NPP2 (ENPP2), which has since become the gene symbol for ATX<sup>[<xref rid="b23" ref-type="bibr">23</xref>]</sup>. However, it was not clear how this extracellular nucleotide activity could explain the motility-stimulating capability of ATX described in melanoma cell culture. This mystery remained until 2002, when the plasma lysoPLD activity described in 1986 was purified and found to be identical to ATX<sup>[<xref rid="b24" ref-type="bibr">24</xref>-<xref rid="b26" ref-type="bibr">26</xref>]</sup>. Subsequent work showed that ATX/ENPP2 was unique among the NPPs/ENPPs because of its lysoPLD activity, which converts LPC to LPA<sup>[<xref rid="b24" ref-type="bibr">24</xref>]</sup>. The affinity of ATX for LPC was shown to be higher than for nucleotides, suggesting that LPC is the preferred physiological substrate for ATX <sup>[<xref rid="b24" ref-type="bibr">24</xref>]</sup>. The motility-stimulating function of ATX was enhanced by addition of LPC to cell culture experiments, and this action could be mimicked by direct addition of LPA<sup>[<xref rid="b8" ref-type="bibr">8</xref>,<xref rid="b24" ref-type="bibr">24</xref>]</sup>. Furthermore, deletion of LPA<sub>1</sub> receptors in fibroblasts abolished the effects of ATX on cell migration<sup>[<xref rid="b27" ref-type="bibr">27</xref>]</sup>. Thus, LPA, the product of ATX, is the actual &#x0201c;motility factor&#x0201d;.</p><p>ATX is a vital enzyme that is needed for proper early embryological development. ATX knockout (KO) (ENPP2<sup>-/-</sup>) embryos die <italic>in utero</italic> on day 9.5 with vascular and neural tube defects<sup>[<xref rid="b28" ref-type="bibr">28</xref>-<xref rid="b31" ref-type="bibr">31</xref>]</sup>. In these mice, malformations in the allantois, neural tube and headfold are detected by day 8.5, and at day 10.5 embryos become necrotic and are reabsorbed<sup>[<xref rid="b32" ref-type="bibr">32</xref>]</sup>. Normally, extra-embryonic endothelial cells remodel from day 8.5 to 9.5 to create a vascular network that connects with the embryo, allowing the yolk sac to function as the main nutrient source. ENPP2<sup>-/-</sup> embryos have increased expression of VEGF mRNA, consistent with hypoxic conditions in the absence of a functional vascular system<sup>[<xref rid="b28" ref-type="bibr">28</xref>,<xref rid="b33" ref-type="bibr">33</xref>]</sup>.</p><p>Neural tube closure typically begins at day 8.5. The neural tube closure defects in ENPP2<sup>-/-</sup> embryos have been attributed to a local deficiency in ATX expression<sup>[<xref rid="b28" ref-type="bibr">28</xref>]</sup>. In ENPP2<sup>-/-</sup> embryo explants, these folding abnormalities are abrogated by exogenous addition of LPA<sup>[<xref rid="b34" ref-type="bibr">34</xref>]</sup>. The role of ATX in vascular and neural development has also been confirmed in zebrafish<sup>[<xref rid="b32" ref-type="bibr">32</xref>,<xref rid="b35" ref-type="bibr">35</xref>]</sup>. ATX regulates oligodendrocyte differentiation in the developing zebrafish hindbrain<sup>[<xref rid="b36" ref-type="bibr">36</xref>]</sup> and the correct left-right asymmetry for normal organ morphogenesis through Wnt-dependent pathways<sup>[<xref rid="b37" ref-type="bibr">37</xref>]</sup>. ENPP2<sup>+/-</sup> mice are viable, and express half the levels of both ATX and LPA compared to normal mice<sup>[<xref rid="b38" ref-type="bibr">38</xref>]</sup>. However, they are hyper-responsive to hypoxiainduced vasoconstriction and remodeling, and they develop pulmonary hypertension<sup>[<xref rid="b38" ref-type="bibr">38</xref>]</sup>.</p><p>One of the important roles of ATX after birth is in wound healing and tissue remodeling. LPA is a potent activator of platelet aggregation and it stimulates the division and migration of fibroblasts, vascular smooth muscle cells, endothelial cells and keratinocytes<sup>[<xref rid="b39" ref-type="bibr">39</xref>]</sup>. Increased ATX activity is found in blister fluid where local production of LPA promotes re-epithelialization<sup>[<xref rid="b40" ref-type="bibr">40</xref>]</sup>. ATX expression and LPA production are also increased in rabbit aqueous humor following corneal freeze wounds<sup>[<xref rid="b41" ref-type="bibr">41</xref>]</sup>. Recently discovered physiological roles for ATX include hair follicle morphogenesis<sup>[<xref rid="b42" ref-type="bibr">42</xref>]</sup>, bone mineralization<sup>[<xref rid="b43" ref-type="bibr">43</xref>]</sup> and myeloid differentiation in human bone marrow<sup>[<xref rid="b44" ref-type="bibr">44</xref>]</sup>. ATX/LPA signaling also remodels luteal tissue in regressing corpora lutea of cycling rats by recruiting phagocytes and proliferating fibroblasts<sup>[<xref rid="b45" ref-type="bibr">45</xref>]</sup>. ATX expression is also upregulated in microglia in response to oxidative stress. This protects microglia cells against damage from H<sub>2</sub>O<sub>2</sub>, an effect which is partially reversed in the presence of the mixed LPA<sub>1/3</sub> antagonist Ki16425<sup>[<xref rid="b46" ref-type="bibr">46</xref>]</sup>. A follow-up study showed that ATX overexpression in microglia limited the pro-inflammatory response to lipopolysaccharide exposure, mimicking Gram-negative infection<sup>[<xref rid="b47" ref-type="bibr">47</xref>]</sup>. ATX is expressed in high endothelial venules (HEVs) in lymph nodes and other secondary lymphoid tissues<sup>[<xref rid="b48" ref-type="bibr">48</xref>]</sup> and mediates lymphocyte extravasation, which is crucial for maintaining immune homeostasis<sup>[<xref rid="b49" ref-type="bibr">49</xref>-<xref rid="b51" ref-type="bibr">51</xref>]</sup>. However, in chronically inflamed tissues, ATX mediates lymphocyte trafficking and upregulates cytokine production in response to repeated microinjuries and incomplete tissue repair<sup>[<xref rid="b52" ref-type="bibr">52</xref>-<xref rid="b54" ref-type="bibr">54</xref>]</sup>.</p><p>We recently showed that ATX expression is negatively regulated by LPA signaling through increased phosphatidylinositol 3-kinase (PI3K); however, this inhibition is overcome by pro-inflammatory cytokines<sup>[<xref rid="b55" ref-type="bibr">55</xref>]</sup>. The production of inflammatory cytokines, such as in damaged and inflamed tissue, is a signal for increased ATX expression and LPA production to heal the wound<sup>[<xref rid="b39" ref-type="bibr">39</xref>,<xref rid="b56" ref-type="bibr">56</xref>]</sup>. If this process is successful and inflammation subsides, then LPA produced by ATX feeds back and blocks further ATX production. However, if inflammation is unresolved, inflammatory cytokines stimulate further ATX production and consequent LPA formation stimulates more cytokine production in a vicious cycle<sup>[<xref rid="b56" ref-type="bibr">56</xref>]</sup>.</p><p>The initial relation of ATX/LPA signaling with melanoma cells resulted in much of the early research into ATX being concentrated in the cancer field<sup>[<xref rid="b39" ref-type="bibr">39</xref>,<xref rid="b57" ref-type="bibr">57</xref>-<xref rid="b65" ref-type="bibr">65</xref>]</sup>. LPA increases vascular endothelial growth factor (VEGF) production, which stimulates angiogenesis<sup>[<xref rid="b66" ref-type="bibr">66</xref>]</sup>, a process necessary for tumor progression. LPA decreases the expression of the tumor suppressor p53<sup>[<xref rid="b67" ref-type="bibr">67</xref>]</sup>, thus increasing cancer cell survival and division. We discovered that LPA produces resistance to the cytotoxic effects of paclitaxel, a first line treatment for breast cancer<sup>[<xref rid="b9" ref-type="bibr">9</xref>,<xref rid="b15" ref-type="bibr">15</xref>,<xref rid="b68" ref-type="bibr">68</xref>]</sup>. This was confirmed<sup>[<xref rid="b69" ref-type="bibr">69</xref>]</sup> and extended since LPA produces resistance to the apoptotic effects of carboplatin<sup>[<xref rid="b70" ref-type="bibr">70</xref>]</sup> and radiation-induced cell death<sup>[<xref rid="b14" ref-type="bibr">14</xref>-<xref rid="b15" ref-type="bibr">15</xref>,<xref rid="b71" ref-type="bibr">71</xref>]</sup>. LPA levels as high as 10 &#x003bc;mol/L have been reported in ascites fluid of advanced ovarian cancer patients<sup>[<xref rid="b5" ref-type="bibr">5</xref>]</sup>. Mice that overexpress ATX in mammary epithelium develop spontaneous metastatic mammary tumors<sup>[<xref rid="b72" ref-type="bibr">72</xref>]</sup>. Further, the ATX gene is among the top 40 most upregulated genes in metastatic cancers<sup>[<xref rid="b73" ref-type="bibr">73</xref>]</sup>. ATX/LPA signaling is positively correlated with the invasive and metastatic potential of several cancers including melanoma, breast cancer, ovarian cancer, thyroid cancer, renal cell cancer, lung cancer, neuroblastoma, hepatocellular carcinoma and glioblastoma multiforme<sup>[<xref rid="b15" ref-type="bibr">15</xref>,<xref rid="b74" ref-type="bibr">74</xref>]</sup>.</p><p>However, the tumor is a heterogeneous environment composed of many different cell types including fibroblasts, endothelial cells and leukocytes in addition to cancer cells. There are also a host of soluble molecules in the tumor and this heterogeneity adds another layer of complexity to ATX/LPA signaling. Popnikolov <italic>et al.</italic> showed that immunohistochemical staining for ATX in stromal cells and LPA<sub>3</sub> and cancer epithelial cells correlate positively with cancer aggressiveness<sup>[<xref rid="b75" ref-type="bibr">75</xref>]</sup>. This study highlights the role of ATX from tumor stroma as a producer of LPA for cancer progression. We have since shown that breast cancer cells are very poor expressers of ATX and instead breast tumors in mice induce ATX in adjacent mammary adipose tissue<sup>[<xref rid="b76" ref-type="bibr">76</xref>]</sup>. More recent work has shown that metastasis of breast cancer cells to bone depends on the interaction of platelet-derived ATX with &#x003b1;<sub>V</sub>&#x003b2;<sub>3</sub> integrins on cancer cells<sup>[<xref rid="b77" ref-type="bibr">77</xref>]</sup>. Hence, in tumors like neuroblastomas, melanomas and thyroid carcinomas, the cancer cells may be abundant producers of ATX whereas in other tumors like breast, the cancer cells may instead rely on ATX produced from other tissues such as adjacent adipose tissue or in platelets for metastatic cells. A more extensive overview of ATX production in cancer and other diseases has been previously reviewed<sup>[<xref rid="b56" ref-type="bibr">56</xref>,<xref rid="b78" ref-type="bibr">78</xref>,<xref rid="b79" ref-type="bibr">79</xref>]</sup>.</p></sec><sec id="s2b"><title>LPA receptor diversity and signaling</title><p>To date, there are at least six known LPA receptors, all of which are G-protein-coupled (GPCRs) (<xref ref-type="fig" rid="f01"><bold><italic>Fig. 1</italic></bold></xref>)<sup>[<xref rid="b80" ref-type="bibr">80</xref>]</sup>. GPCRs are integral membrane proteins composed of a single polypeptide with seven transmembrane domains. GPCRs transmit the signals from extracellular stimuli to intracellular signals through activation of a heterotrimeric guanosine triphosphatebinding protein (G-protein) by the receptor, which involves dissociation of the G&#x003b1; subunit from the G&#x003b2;&#x003b3; subunits by exchange of a guanosine diphosphate (GDP) for a guanosine triphosphate (GTP). These subunits, particularly the G&#x003b1; subunit, interact with a host of downstream effectors to elicit an intracellular response.</p><p>The first three of the LPA receptors, LPA<sub>1-3</sub>, belong to the Edg (endothelial differentiation gene) family<sup>[<xref rid="b80" ref-type="bibr">80</xref>]</sup>. These are the best understood and most studied of the LPA receptors. LPA<sub>1</sub>/EDG2 was the first to be discovered in 1996, followed soon after by LPA<sub>2</sub>/EDG4 and LPA<sub>3</sub>/EDG7<sup>[<xref rid="b81" ref-type="bibr">81</xref>-<xref rid="b84" ref-type="bibr">84</xref>]</sup>. These receptors have a ubiquitous distribution, and the other five GPCRs in the Edg-subfamily are receptors for sphingosine-1-phosphate (S1P) (S1P<sub>1-5</sub>), which is the sphingolipid analog of LPA<sup>[<xref rid="b80" ref-type="bibr">80</xref>]</sup>. Knockout (KO) mice have been generated for all the known LPA receptors, as well as double KOs for combinations of LPA<sub>1-3</sub> and the triple KO of LPA<sub>1-3</sub>, all of which are viable<sup>[6,85-86]</sup>. LPA<sub>1</sub> deletion shows craniofacial deformity while LPA<sub>3</sub> deletion leads to delayed implantation of embryos and impaired embryo spacing<sup>[<xref rid="b87" ref-type="bibr">87</xref>-<xref rid="b88" ref-type="bibr">88</xref>]</sup>. No obvious phenotypic defect has been found in LPA<sub>2</sub> KO mice <sup>[<xref rid="b89" ref-type="bibr">89</xref>]</sup>. These findings underscore the redundancy of LPA-receptor signaling pathways and also suggest that there may be other receptors that can mediate LPA signaling.</p><p>LPA<sub>4-6</sub> belong to the P2Y purinergic family of receptors and have specific tissue distributions unlike LPA<sub>1-3</sub>
<sup>[<xref rid="b80" ref-type="bibr">80</xref>-<xref rid="b90" ref-type="bibr">90</xref>]</sup>. LPA4/GPR23/p3y9 is found in the embryonically developing brain and in adults largely in the ovaries<sup>[<xref rid="b91" ref-type="bibr">91</xref>-<xref rid="b92" ref-type="bibr">92</xref>]</sup>. LPA<sub>5</sub>/GPR92 is highly expressed in the spleen, small intestine and dorsal root ganglion cells<sup>[<xref rid="b93" ref-type="bibr">93</xref>]</sup>. In mast cells, LPA<sub>5</sub> is the main LPA receptor responsible for LPA-induced release of chemokine (C-C motif) ligand 4 (CCL4/MIP-1&#x003b2;)<sup>[<xref rid="b94" ref-type="bibr">94</xref>]</sup>. Genetic ablation of either LPA<sub>4</sub> or LPA<sub>5</sub> does not result in obvious phenotypic defects<sup>[<xref rid="b95" ref-type="bibr">95</xref>-<xref rid="b96" ref-type="bibr">96</xref>]</sup>. LPA<sub>6</sub>/p2y5 appears to be important for hair growth since genetic truncations of the receptor leads to hypotrichosis simplex, a set of diseases involving familial hair loss<sup>[<xref rid="b97" ref-type="bibr">97</xref>]</sup>. <italic>In vitro</italic>, this receptor only responds to &#x003bc;M concentrations of LPA while LPA<sub>1-5</sub> will activate in response to nM concentrations<sup>[<xref rid="b98" ref-type="bibr">98</xref>]</sup>. Finally, there are at least three more proposed LPA receptors (GPR87, P2Y10 and GPR35), but their specificity for LPA requires further experimental validation<sup>[<xref rid="b80" ref-type="bibr">80</xref>]</sup>.</p><p>Overall, LPA signaling through at least six known G-protein-coupled receptors (LPA<sub>1-6</sub>) stimulates cell survival and migration through the relative activations of (PI3K), ERK<sub>1/2</sub>, mTOR, Ca<sup>2+</sup>-transients, Rac, Rho and Ras, and these receptors are often overexpressed in cancer cells<sup>[<xref rid="b15" ref-type="bibr">15</xref>]</sup>. Like for ATX, mice that overexpress LPA<sub>1</sub>, LPA<sub>2</sub> or LPA<sub>3</sub> in mammary epithelium develop spontaneous metastatic mammary tumors<sup>[<xref rid="b72" ref-type="bibr">72</xref>]</sup>. LPA<sub>1</sub> and/or LPA<sub>2</sub> receptors are overexpressed in many cancers, particularly gastric, ovarian, breast, colorectal and thyroid cancers compared to healthy tissues<sup>[<xref rid="b99" ref-type="bibr">99</xref>-<xref rid="b104" ref-type="bibr">104</xref>]</sup>. In melanoma, LPA<sub>3</sub> is the dominant receptor subtype, and LPA<sub>3</sub> overexpression in rat hepatoma cells enhances tumor growth and cell migration<sup>[<xref rid="b7" ref-type="bibr">7</xref>,<xref rid="b105" ref-type="bibr">105</xref>]</sup>. Little cancer research has focused on LPA<sub>4-6</sub>, however, one study showed an increase in the unmethylated state of LPA<sub>5</sub>-encoding DNA in lung and hepatic cancer cell lines compared to normal tissues<sup>[<xref rid="b106" ref-type="bibr">106</xref>]</sup>. KO mice for LPA<sub>1</sub> and LPA<sub>5</sub> have fewer lung metastatic nodules compared to wild-type mice following tail vein injection of cancer cells<sup>[<xref rid="b107" ref-type="bibr">107</xref>]</sup>. This finding suggests that LPA signaling in host tissue is important for establishing a permissible microenvironment for metastatic cancer cells to form new tumors. Targeting LPA receptors as a means of treating disease is discussed later on in this review, and more extensive reviews on LPA receptors are found elsewhere<sup>[<xref rid="b90" ref-type="bibr">90</xref>,<xref rid="b108" ref-type="bibr">108</xref>-<xref rid="b109" ref-type="bibr">109</xref>]</sup>.</p></sec><sec id="s2c"><title>LPPs as regulators of extracellular LPA signaling</title><p>In mammals, LPPs consist of three isoforms: LPP1, LPP2 and LPP3. They share highly conserved catalytic domains and catalyze the dephosphorylation of a variety of lipid phosphates, including phosphatidate, LPA, S1P, ceramide 1-phosphate and diacylglycerol pyrophosphate<sup>[<xref rid="b110" ref-type="bibr">110</xref>]</sup>. LPPs are integral membrane proteins, which are localized on plasma membranes with the active site on the outer leaflet. This enables the LPPs to degrade extracellular LPA and other signaling lipids, attenuating their effects on surface receptor activation<sup>[<xref rid="b110" ref-type="bibr">110</xref>]</sup>. The importance of this ecto-activity has been demonstrated <italic>in vivo</italic> where the half-life of circulating LPA increases from 3 minutes to 12 minutes in LPP1 hypomorph mice compared to normal control littermates<sup>[<xref rid="b111" ref-type="bibr">111</xref>]</sup>. LPPs are also localized on the internal membranes including the endoplasmic reticulum<sup>[<xref rid="b112" ref-type="bibr">112</xref>]</sup> and Golgi network<sup>[<xref rid="b113" ref-type="bibr">113</xref>]</sup>, where presumably the catalytic domains face the lumenal sides of these organelles. As such, intracellular LPPs could potentially regulate signal transduction through dephosphorylation of lipid phosphates inside cells as opposed to the degradation of extracellular LPA or S1P<sup>[<xref rid="b110" ref-type="bibr">110</xref>]</sup>. Evidence for this was first obtained from experiments in which increasing the expression of LPP1, LPP1a (a spice variant) and LPP2 decreased thrombin-induced ERK activation<sup>[<xref rid="b114" ref-type="bibr">114</xref>]</sup>. Increasing LPP1 expression also attenuated fibroblast migration in response to an LPA<sub>1/2</sub> agonist (wls-31), which cannot be dephosphorylated<sup>[<xref rid="b115" ref-type="bibr">115</xref>]</sup>. Later work with cancer cells showed that increasing LPP1 expression decreased the activation of Ca<sup>2+</sup>-transients by wls-31 and a protease-activated receptor-1 peptide<sup>[<xref rid="b116" ref-type="bibr">116</xref>]</sup>. These effects depend on the catalytic activity of LPP1, but the lipid phosphate which is degraded by LPP1 is not yet known. Since the substrates of LPPs also exist inside cells, degradation of unidentified intracellular substrates could be one of the explanations for the intracellular functions of LPPs.</p><p>The LPPs and their role in cancer biology are emerging fields of study. Significantly, LPP1 expression is decreased in many cancers including ovarian, renal, leukemia, colorectal, melanoma and lung cancers compared to normal tissues<sup>[<xref rid="b116" ref-type="bibr">116</xref>]</sup>. Increasing LPP1 expression in ovarian cancer cells increases extracellular LPA hydrolysis, deceases cell proliferation and colonyforming activity, and increases apoptosis<sup>[<xref rid="b117" ref-type="bibr">117</xref>]</sup>. Virtually identical results in ovarian cancer cell lines have been obtained through overexpression of LPP3<sup>[<xref rid="b118" ref-type="bibr">118</xref>]</sup>. However, there is one report that LPP3 overexpression actually increases tumor growth in glioblastoma models by increasing &#x003b2;-catenin stability and cyclin D1 synthesis. LPP3 is highly expressed in human primary glioblastoma tumors<sup>[<xref rid="b119" ref-type="bibr">119</xref>]</sup>. Rather than targeting LPP signaling in cancer cells, Nakayama <italic>et al.</italic> recently examined the contribution of LPP1 expression in the tumor microenvironment to cancer cell seeding<sup>[<xref rid="b120" ref-type="bibr">120</xref>]</sup>. Intraperitoneal injection of syngeneic ovarian cancer cells into LPP1 knockout mice leads to enhanced cancer cell seeding compared to wildtype mice<sup>[<xref rid="b120" ref-type="bibr">120</xref>]</sup>. Presumably, higher systemic levels of LPA can explain this result as a consequence of decreased LPA turnover in LPP1 knockout mice compared to wildtype controls<sup>[<xref rid="b111" ref-type="bibr">111</xref>,<xref rid="b120" ref-type="bibr">120</xref>]</sup>. Other work on targeting LPP expression or investigations to its role in tumor biology is presented later in this review.</p><p>Thus far, the relationship between LPP2 expression and cancer is unclear. Work in our laboratory showed that overexpression of LPP2 in fibroblasts causes premature entry into S-phase of the cell cycle, whereas knockdown of LPP2 delays entry by 1.5 hours<sup>[<xref rid="b121" ref-type="bibr">121</xref>]</sup>. Similar effects could not be obtained with either overexpression or knockdown of LPP1/3, suggesting that LPP2 might have a unique role among the LPPs in cell cycle regulation<sup>[<xref rid="b121" ref-type="bibr">121</xref>]</sup>. Genomic screens showed LPP2 (<italic>PPAP2C</italic>) to be upregulated in transformed human adult mesenchymal stem cells. In the same study, knockdown of LPP2 impaired anchorage-dependent growth of cancers cells and mesenchymal stem cells<sup>[<xref rid="b122" ref-type="bibr">122</xref>]</sup>. This work replicated our S-phase cell cycle findings, and further showed LPP2 to be negatively regulated by p53, a major tumor suppressor<sup>[<xref rid="b122" ref-type="bibr">122</xref>]</sup>. More information on the LPPs and related proteins can be obtained by reference to other reviews<sup>[<xref rid="b10" ref-type="bibr">10</xref>,<xref rid="b39" ref-type="bibr">39</xref>,<xref rid="b110" ref-type="bibr">110</xref>,<xref rid="b123" ref-type="bibr">123</xref>]</sup>.</p></sec></sec><sec id="s3"><title>Targeting the ATX/LPA/LPP axis <italic>in vivo</italic></title><p>Currently, several strategies are being investigated to target ATX/LPA signaling at multiple levels: by monoclonal antibody therapy against LPA, antagonizing LPA receptor signaling, attenuating LPA signaling by increasing LPP1 or LPP3 activities and by blocking LPA production through inhibition of ATX activity (<xref ref-type="fig" rid="f01"><bold><italic>Fig. 1</italic></bold></xref>). We will now summarize current progress in each of these areas.</p><sec id="s3a"><title>LPA monocolonal antibodies</title><p>Antibody-mediated therapy is advantageous over traditional therapeutics in that it is extremely selective in its targeting and is very stable once delivered intravenously<sup>[<xref rid="b124" ref-type="bibr">124</xref>]</sup>. Normal immunological processes usually only clear antibodies once they bind to their targets and thus have a long bioavailability. For LPA as a target, all published work thus far comes from Lpath Inc. in San Diego. Their first work determined the X-ray crystal structure of LPA bound to the humanized monoclonal anti-LPA antibody LT3015<sup>[<xref rid="b125" ref-type="bibr">125</xref>]</sup>. They found that both heavy and light chain loops of the antibody create eight hydrogen bonds with the glycerophosphate headgroup of LPA<sup>[<xref rid="b125" ref-type="bibr">125</xref>]</sup>. Furthermore, the antibody had no binding affinity to S1P, LPC, PA or PC<sup>[<xref rid="b125" ref-type="bibr">125</xref>]</sup>.</p><p>Blocking LPA signaling with another monoclonal antibody, called B3, improved spinal cord injury outcomes in both zebrafish and mouse models<sup>[<xref rid="b126" ref-type="bibr">126</xref>]</sup>. When treated with B3, there was reduced glial inflammation and neuronal cell death, leading to increased neuronal survival upstream of the injury and consequently some improvement in function<sup>[<xref rid="b126" ref-type="bibr">126</xref>]</sup>. B3 was later renamed Lpathomab<sup>TM</sup>, and in a follow up study, treatment with Lpathomab<sup>TM</sup> reduced IL-6 expression and lesion volume, and improved functional outcomes in a mouse model of traumatic brain injury<sup>[<xref rid="b127" ref-type="bibr">127</xref>]</sup> (<xref ref-type="table" rid="t01"><bold><italic>Table 1</italic></bold></xref>). The authors also quantified increases in LPA in the cerebrospinal fluid of human patients and mice with traumatic brain injuries relative to controls. This led the authors to conclude that anti-LPA antibody therapy could have neuroprotective effects following injury<sup>[<xref rid="b127" ref-type="bibr">127</xref>]</sup>. Lpath Inc. has begun the process of entering Lpathomab<sup>TM</sup> into clinical trials<sup>[<xref rid="b128" ref-type="bibr">128</xref>]</sup>.</p><table-wrap id="t01" position="float"><label>Table 1</label><caption><title>Overview of targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis <italic>in vivo</italic>.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Chemical/Technique</th><th align="center" rowspan="1" colspan="1">Function</th><th align="center" rowspan="1" colspan="1">Stage</th><th align="center" rowspan="1" colspan="1">Pharmacological/ Dosing Parameters</th><th align="center" rowspan="1" colspan="1">Applications [Refs]</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">PF-8380</td><td align="left" rowspan="1" colspan="1">Autotaxin activity inhibitor (competitive)</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">IC<sub>50</sub> 101 nmol/L<break/>30 mg/kg</td><td align="left" rowspan="1" colspan="1">Inflammatory hyperalgesia<sup>[<xref rid="b140" ref-type="bibr">140</xref>]</sup><break/>Radiotherapy sensitizer in glioblastoma<sup>[<xref rid="b146" ref-type="bibr">146</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">ONO-8430506</td><td align="left" rowspan="1" colspan="1">Autotaxin activity inhibitor (competitive)</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">IC<sub>50</sub> 5 nmol/L<break/>10-30 mg/kg</td><td align="left" rowspan="1" colspan="1">Benign prostatic hyperplasia<sup>[<xref rid="b147" ref-type="bibr">147</xref>]</sup><break/>Reduces breast tumor growth and metastasis and increases sensitization to doxorubicin<sup>[<xref rid="b76" ref-type="bibr">76</xref>,<xref rid="b148" ref-type="bibr">148</xref>]</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Lpathomab<sup>TM</sup></td><td align="left" rowspan="1" colspan="1">LPA monoclonal antibody</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">25 mg/kg</td><td align="left" rowspan="1" colspan="1">Traumatic brain injury<sup>[<xref rid="b127" ref-type="bibr">127</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">AM966</td><td align="left" rowspan="1" colspan="1">LPA<sub>1</sub> antagonist</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">IC<sub>50</sub> 17 nmol/L<break/>10 mg/kg</td><td align="left" rowspan="1" colspan="1">Idiopathic pulmonary fibrosis<sup>[<xref rid="b132" ref-type="bibr">132</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">BMS-986020</td><td align="left" rowspan="1" colspan="1">LPA<sub>1</sub> antagonist</td><td align="left" rowspan="1" colspan="1">Phase II</td><td align="left" rowspan="1" colspan="1">600 mg/day (patients)</td><td align="left" rowspan="1" colspan="1">Idiopathic pulmonary fibrosis<sup>[<xref rid="b133" ref-type="bibr">133</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">BMS-986202/AM152</td><td align="left" rowspan="1" colspan="1">LPA<sub>1</sub> antagonist</td><td align="left" rowspan="1" colspan="1">Phase I</td><td align="left" rowspan="1" colspan="1">20-40 mg/kg</td><td align="left" rowspan="1" colspan="1">Idiopathic pulmonary fibrosis<sup>[<xref rid="b134" ref-type="bibr">134</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">SAR100842</td><td align="left" rowspan="1" colspan="1">LPA<sub>1/3</sub> antagonist</td><td align="left" rowspan="1" colspan="1">Phase II</td><td align="left" rowspan="1" colspan="1">20-40 mg/kg</td><td align="left" rowspan="1" colspan="1">Systemic sclerosis<sup>[<xref rid="b135" ref-type="bibr">135</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Gene overexpression</td><td align="left" rowspan="1" colspan="1">Induced <italic>LPP</italic> gene expression</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">Overexpressed in cancer cells</td><td align="left" rowspan="1" colspan="1">LPP3 overexpression reduces ovarian cancer cell growth<sup>[<xref rid="b118" ref-type="bibr">118</xref>]</sup><break/>LPP1 overexpression reduces tumor growth and metastasis in breast and thyroid cancers<sup>[<xref rid="b116" ref-type="bibr">116</xref>]</sup></td></tr></tbody></table></table-wrap></sec><sec id="s3b"><title>LPA receptor antagonists</title><p>Thus far, there are dozens of known LPA receptor antagonists, but few are effective <italic>in vivo</italic><sup>[<xref rid="b54" ref-type="bibr">54</xref>]</sup>. They can be broadly classified into lipid mimetics or small molecule inhibitors. Virtually all research into LPA receptor antagonist therapy comes from studies of fibrotic models<sup>[<xref rid="b54" ref-type="bibr">54</xref>,<xref rid="b108" ref-type="bibr">108</xref>,<xref rid="b129" ref-type="bibr">129</xref>]</sup>. LPA accelerates lung fibrosis by differentiating mesenchymal stem cells into myofibroblasts through LPA<sub>1</sub> signaling in idiopathic pulmonary fibrosis (IPF). This is a disease of interstitial infiltrates in the lungs characterized by progressive shortness of breath and worsening pulmonary function<sup>[<xref rid="b130" ref-type="bibr">130</xref>-<xref rid="b131" ref-type="bibr">131</xref>]</sup>. This process is slowed in bleomycin-induced IPF mouse models with the LPA<sub>1</sub> antagonist AM966<sup>[<xref rid="b132" ref-type="bibr">132</xref>]</sup>. To date, there are at least three LPA<sub>1</sub> antagonists in phase I/II clinical trials for IPF<sup>[<xref rid="b108" ref-type="bibr">108</xref>,<xref rid="b133" ref-type="bibr">133</xref>-<xref rid="b135" ref-type="bibr">135</xref>]</sup> (<xref ref-type="table" rid="t01"><bold><italic>Table 1</italic></bold></xref>).</p><p>Scleroderma is also a fibrotic disease characterized by hardening of the skin and is a chronic systemic autoimmune disease<sup>[<xref rid="b136" ref-type="bibr">136</xref>]</sup>. Significantly, C20:4-LPA levels are two-fold higher in the serum of scleroderma patients compared to healthy controls<sup>[<xref rid="b137" ref-type="bibr">137</xref>]</sup>. Studies with LPA<sub>1</sub> KO mice show protection against scleroderma<sup>[<xref rid="b138" ref-type="bibr">138</xref>]</sup>, and phase II clinical trials of the LPA<sub>1/3</sub> inhibitor SAR100842 are underway for systemic sclerosis<sup>[<xref rid="b108" ref-type="bibr">108</xref>]</sup>. We refer the reader to other reviews that discuss LPA antagonists in greater detail<sup>[<xref rid="b90" ref-type="bibr">90</xref>,<xref rid="b108" ref-type="bibr">108</xref>-<xref rid="b109" ref-type="bibr">109</xref>]</sup>.</p><p>Most efforts from the pharmaceutical industry have been based on the development of LPA<sub>1</sub>-selective, LPA<sub>2</sub>-selective, and LPA<sub>1/3</sub> dual antagonists, since LPA<sub>1</sub> and LPA<sub>3</sub>-mediated signaling is overlapping<sup>[<xref rid="b54" ref-type="bibr">54</xref>]</sup>. However, to address the issue of signaling redundancy among the LPA receptors, there is a debate as to whether a more effective approach would be to develop pan-LPA receptor antagonists<sup>[<xref rid="b54" ref-type="bibr">54</xref>]</sup>. Ultimately, drug design approaches need to balance efficacy with safety, and a hypothetical pan-antagonist is more likely to have cross-reactivity with other unintended G-protein-coupled receptors than an antagonist designed specifically to interact with one or two receptors. Such antagonists would likely have to be delivered directly to the organ of treatment to limit otherwise increased systemic side effects compared to simpler oral, subcutaneous and/or intravenous administration options<sup>[<xref rid="b54" ref-type="bibr">54</xref>]</sup>.</p></sec><sec id="s3c"><title>Increasing LPP expression as a cancer therapy</title><p>To date little is known about how to increase the low expression of LPP1 and LPP3 in cancer cells. One early study showed gonadotropin-releasing hormone increased LPP activity in ovarian cancer cells expressing the gonadotropin-releasing hormone receptor<sup>[<xref rid="b139" ref-type="bibr">139</xref>]</sup>. This work with cultured cancer cells was validated by measuring tumor growth from SKOV3 ovarian carcinoma cells in nude mice. Cells that over-expressed hLPP3 showed lower tumor growth<sup>[<xref rid="b118" ref-type="bibr">118</xref>]</sup> (<xref ref-type="table" rid="t01"><bold><italic>Table 1</italic></bold></xref>). The authors ascribed this result to the ecto-phosphatase activities of LPP3 at a time when the effects that occur downstream of receptor activation were not widely appreciated.</p><p>In our laboratory, we showed that overexpression of LPP1 in breast and thyroid cancer cell lines decreases tumor growth and metastasis by up to 80% compared with the expression of catalytically inactive LPP1 in both syngeneic and xenograft mouse models<sup>[<xref rid="b116" ref-type="bibr">116</xref>]</sup> (<xref ref-type="table" rid="t01"><bold><italic>Table 1</italic></bold></xref>). We also demonstrated that these effects on the cancer cells cannot be explained by the increased ecto-activity, which degrades exogenous LPA or S1P. Instead, the main action of LPP1 is mediated downstream of receptor activation since LPP1 overexpression also decreased the stimulation of Ca<sup>2+</sup>-transients by the stable LPA<sub>1/2</sub> receptor agonist wls-31<sup>[<xref rid="b116" ref-type="bibr">116</xref>]</sup>. LPP1 expression also decreased Ca<sup>2+</sup>-transients that resulted from activation by a protease-activated receptor-1 agonist peptide, which acts independently of LPA signaling. At present, we do not know what substrate LPP1 acts on intra-cellularly to modify cell signaling and slow tumor progression.</p></sec><sec id="s3d"><title>ATX inhibitors</title><p>ATX inhibitors hold great potential to treat a multitude of diseases mediated by LPA signaling, particularly cancer and other chronic inflammatory-mediated diseases<sup>[<xref rid="b56" ref-type="bibr">56</xref>,<xref rid="b79" ref-type="bibr">79</xref>]</sup>. Because LPA is rapidly turned over, plasma LPA levels fall by &#x0003e;95% upon treatment with a potent ATX inhibitor<sup>[<xref rid="b140" ref-type="bibr">140</xref>]</sup>. There are numerous small non-lipid molecules that have been discovered and modified to inhibit ATX activity through screening large libraries of compounds<sup>[<xref rid="b141" ref-type="bibr">141</xref>-<xref rid="b142" ref-type="bibr">142</xref>]</sup>. Unlike classical lipid analogs, these inhibitors tend to have better oral bioavailability due to their decreased hydrophobicity and they are unlikely to be degraded rapidly by endogenous hydrolytic pathways<sup>[<xref rid="b143" ref-type="bibr">143</xref>]</sup>. A more thorough history of ATX inhibitor development has been published previously<sup>[<xref rid="b56" ref-type="bibr">56</xref>,<xref rid="b79" ref-type="bibr">79</xref>,<xref rid="b109" ref-type="bibr">109</xref>,<xref rid="b141" ref-type="bibr">141</xref>,<xref rid="b144" ref-type="bibr">144</xref>]</sup>, and here we will discuss work on ATX-specific inhibitors that have been used <italic>in vivo</italic>.</p><p>PF-8380, a piperazinylbenzoxazolone derivative, was developed by Pfizer from screening a compound library followed by optimization. PF-8380 has an IC<sub>50</sub> of 2.8 nmol/L against recombinant human ATX and 101 nmol/L for whole human blood. It was the first reported ATX inhibitor to reduce plasma LPA levels <italic>in vivo</italic> for an extended period<sup>[<xref rid="b140" ref-type="bibr">140</xref>]</sup>. In rat air-pouch models, 30 mg/kg PF-8380 inhibited inflammatory hyperalgesia with the same efficacy as 30 mg/kg naproxen, a routinely used nonsteroidal anti-inflammatory drug (NSAID)<sup>[<xref rid="b140" ref-type="bibr">140</xref>]</sup>. At this concentration, PF-8380 maximally reduced LPA levels in both plasma and at the site of inflammation. PF-8380 also had radio-sensitizing effects in heterotopic mouse models for glioblastoma multiforme, delaying tumor growth by at least 20 days<sup>[<xref rid="b145" ref-type="bibr">145</xref>-<xref rid="b146" ref-type="bibr">146</xref>]</sup>. In this study, inhibition of ATX by PF-8380 abrogated radiationinduced activation of Akt and subsequently decreased tumor vascularity and tumor growth<sup>[<xref rid="b145" ref-type="bibr">145</xref>]</sup> (<xref ref-type="table" rid="t01"><bold><italic>Table 1</italic></bold></xref>).</p><p>Another potent ATX inhibitor, ONO-8430506, currently in development by Ono Pharmaceuticals Ltd. (Osaka, Japan), is a tetrahydrocarboline derivative with an IC<sub>50</sub> of 5 nmol/L for plasma ATX activity<sup>[<xref rid="b147" ref-type="bibr">147</xref>]</sup>. Dosing rats orally with 30 mg/kg of this compound potently suppressed ATX plasma activity and LPA concentrations for 24 hours and decreased intraurethral pressure in benign prostatic hyperplasia models<sup>[<xref rid="b147" ref-type="bibr">147</xref>]</sup> (<xref ref-type="table" rid="t01"><bold><italic>Table 1</italic></bold></xref>).</p><p>We demonstrated that ONO-8430506 delays initial tumor growth by about 60% in Balb/c mice with orthotopic 4T1 breast tumors for about 10 days. This growth reduction is synergic with doxorubicin and the combined therapy decreases tumor growth by &#x0003e;70% for about 17 days<sup>[<xref rid="b76" ref-type="bibr">76</xref>-<xref rid="b148" ref-type="bibr">148</xref>]</sup> (<xref ref-type="table" rid="t01"><bold><italic>Table 1</italic></bold></xref>). Subsequent lung and liver metastases were also reduced by about 50%-60% with ATX inhibition<sup>[<xref rid="b76" ref-type="bibr">76</xref>,<xref rid="b148" ref-type="bibr">148</xref>]</sup>. In the same studies, we showed for first time that activation of LPA<sub>1</sub> receptors increases the stabilization of the transcription factor, Nrf2, and induces its nuclear translocation<sup>[<xref rid="b148" ref-type="bibr">148</xref>]</sup>. Nrf2 increases the expression of anti-oxidant genes (for example, NADPH-quinone oxidoreductase-1 and hemoxygenase-1), which protects cancer cells against oxidative damage caused by chemotherapy<sup>[<xref rid="b149" ref-type="bibr">149</xref>]</sup>. Also, LPA through Nrf2 increases the expression of the multi-drug resistant transporters, ABCC1, ABCG2, ABCC2 and ABCC3, which export toxic oxidation products and many chemotherapeutic drugs from cancer cells<sup>[<xref rid="b148" ref-type="bibr">148</xref>]</sup>. We confirmed these results <italic>in vivo</italic> by showing that ATX inhibition with ONO-8430506 decreased Nrf2 levels and the expression of anti-oxidant genes and multi-drug resistant transporters in the 4T1 model of breast cancer<sup>[<xref rid="b148" ref-type="bibr">148</xref>]</sup>. This explains why the doxorubicin treatment was more effective in mice that were simultaneously treated with an ATX inhibitor. These responses could also protect against cell death during chemotherapy with a variety of different agents. Our findings prompt the need for further investigations into combination therapy with other common chemotherapies like paclitaxel, as well as with radiotherapy.</p><p>Given the physiological importance of ATX to processes like smooth muscle contraction, platelet aggression and wound healing, we do not know yet if potent ATX inhibition adversely affects tissue repair and remodeling. So far, ATX inhibition studies do not show obvious side effects, but studies using existing wound healing models are warranted<sup>[<xref rid="b150" ref-type="bibr">150</xref>]</sup>. While ATX inhibition is particularly effective at reducing unsaturated and polyunsaturated LPA species, saturated species are decreased less since their production is probably largely mediated by PLA<sub>2</sub> activity<sup>[<xref rid="b7" ref-type="bibr">7</xref>,<xref rid="b151" ref-type="bibr">151</xref>]</sup>. Hence, LPA generation by minor sources like PLA<sub>2</sub> may be sufficient to maintain physiological processes, whereas higher concentrations of unsaturated LPA species from induced ATX expression drive pathological processes. Answers to questions like these are required to determine if ATX inhibitors (as by extension, LPA monoclonal antibodies and LPA receptor antagonists) are contra-indicated in patients with pre-existing wound healing problems, for example, in cases of diabetic neuropathy and autoimmune diseases<sup>[<xref rid="b152" ref-type="bibr">152</xref>]</sup>.</p></sec></sec><sec sec-type="conclusion" id="s4"><title>Conclusion</title><p>Tremendous progress has been made in recent years by targeting the ATX-LPA-LPP axis and now this work is rapidly being translated into clinical trials. We are hopeful that LPA monoclonal antibodies, LPA receptor antagonists and ATX inhibitors will become viable therapeutic interventions within the next decade. With several different pharmacological options, anti-ATX/LPA therapeutics can target all the way from individual receptors with receptor antagonists to systemic voidance of LPA with antibodies and ATX inhibitors. These strategies should be applicable in cancer therapy by providing adjuvants to improve chemotherapy and radiotherapy. Blocking LPA signaling could also provide a novel treatment for several inflammatory diseases.</p></sec></body><back><ack><title>Acknowledgements</title><p>MGKB is the recipient of a Vanier Canada Graduate Scholarship from the Government of Canada, a Canadian Institutes of Health Research (CIHR) MD/PhD Studentship, a MD/PhD Studentship from Alberta Innovates-Health Solutions (AI-HS), and a Killam Trust Award. XT received a post-doctoral fellowship from the Canadian Breast Cancer Foundation (CBCF). GV and RTB received studentships from the Women and Children's Health Research Institute (WCHRI) at the University of Alberta, and GV from AI-HS. The work was also supported by grants from the CBCF, CIHR with WCHRI, and Ono Pharmaceuticals Ltd. The following conflicts of interest are disclosed: DNB has received consulting fees from Ono Pharmaceuticals Ltd. The other authors declare no conflicts of interest.</p></ack><ref-list><title>References</title><ref id="b1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croset</surname><given-names>M</given-names></name><name><surname>Brossard</surname><given-names>N</given-names></name><name><surname>Polette</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Characterization of plasma unsaturated lysophosphatidylcholines in human and rat[J].</article-title>
<source><italic>Biochem J</italic></source>, <year>2000</year>, <volume>345</volume>(<issue>Pt 1</issue>): <fpage>61</fpage>-<lpage>67</lpage>.<pub-id pub-id-type="pmid">10600639</pub-id></mixed-citation></ref><ref id="b2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiesner</surname><given-names>P</given-names></name><name><surname>Leidl</surname><given-names>K</given-names></name><name><surname>Boettcher</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry[J].</article-title>
<source><italic>J Lipid Res</italic></source>, <year>2009</year>, <volume>50</volume>(<issue>3</issue>): <fpage>574</fpage>-<lpage>585</lpage>.<pub-id pub-id-type="pmid">18832345</pub-id></mixed-citation></ref><ref id="b3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eichholtz</surname><given-names>T</given-names></name><name><surname>Jalink</surname><given-names>K</given-names></name><name><surname>Fahrenfort</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>The bioactive phospholipid lysophosphatidic acid is released from activated platelets[J].</article-title>
<source><italic>Biochem J</italic></source>, <year>1993</year>, <volume>291</volume> (<issue>Pt 3</issue>): <fpage>677</fpage>-<lpage>680</lpage>.<pub-id pub-id-type="pmid">8489494</pub-id></mixed-citation></ref><ref id="b4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tigyi</surname><given-names>G</given-names></name><name><surname>Miledi</surname><given-names>R</given-names></name></person-group>
<article-title>Lysophosphatidates bound to serum albumin activate membrane currents in Xenopus oocytes and neurite retraction in PC12 pheochromocytoma cells[J].</article-title>
<source><italic>J Biol Chem</italic></source>, <year>1992</year>, <volume>267</volume>(<issue>30</issue>): <fpage>21360</fpage>-<lpage>21367</lpage>.<pub-id pub-id-type="pmid">1383223</pub-id></mixed-citation></ref><ref id="b5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>DL</given-names></name><name><surname>Morrison</surname><given-names>P</given-names></name><name><surname>Miller</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Plasma lysophosphatidic acid concentration and ovarian cancer[J].</article-title>
<source><italic>JAMA</italic></source>, <year>2002</year>, <volume>287</volume>(<issue>23</issue>): <fpage>3081</fpage>-<lpage>3082</lpage>.<pub-id pub-id-type="pmid">12069669</pub-id></mixed-citation></ref><ref id="b6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakanaga</surname><given-names>K</given-names></name><name><surname>Hama</surname><given-names>K</given-names></name><name><surname>Aoki</surname><given-names>J</given-names></name></person-group>
<article-title>Autotaxin-an LPA producing enzyme with diverse functions[J].</article-title>
<source><italic>J Biochem</italic></source>, <year>2010</year>, <volume>148</volume>(<issue>1</issue>): <fpage>13</fpage>-<lpage>24</lpage>.<pub-id pub-id-type="pmid">20495010</pub-id></mixed-citation></ref><ref id="b7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brindley</surname><given-names>DN</given-names></name><name><surname>Lin</surname><given-names>FT</given-names></name><name><surname>Tigyi</surname><given-names>GJ</given-names></name></person-group>
<article-title>Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy[J].</article-title>
<source><italic>Biochim Biophys Acta</italic></source>, <year>2013</year>, <volume>1831</volume>(<issue>1</issue>): <fpage>74</fpage>-<lpage>85</lpage>.<pub-id pub-id-type="pmid">22954454</pub-id></mixed-citation></ref><ref id="b8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaetano</surname><given-names>CG</given-names></name><name><surname>Samadi</surname><given-names>N</given-names></name><name><surname>Tomsig</surname><given-names>JL</given-names></name><etal/></person-group>
<article-title>Inhibition of autotaxin production or activity blocks lysophosphatidyl-choline-induced migration of human breast cancer and melanoma cells[J].</article-title>
<source><italic>Mol Carcinog</italic></source>, <year>2009</year>, <volume>48</volume>(<issue>9</issue>): <fpage>801</fpage>-<lpage>809</lpage>.<pub-id pub-id-type="pmid">19204929</pub-id></mixed-citation></ref><ref id="b9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samadi</surname><given-names>N</given-names></name><name><surname>Gaetano</surname><given-names>C</given-names></name><name><surname>Goping</surname><given-names>IS</given-names></name><etal/></person-group>
<article-title>Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis[J].</article-title>
<source><italic>Oncogene</italic></source>, <year>2009</year>, <volume>28</volume>(<issue>7</issue>): <fpage>1028</fpage>-<lpage>1039</lpage>.<pub-id pub-id-type="pmid">19079345</pub-id></mixed-citation></ref><ref id="b10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kok</surname><given-names>BP</given-names></name><name><surname>Venkatraman</surname><given-names>G</given-names></name><name><surname>Capatos</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Unlike two peas in a pod: lipid phosphate phosphatases and phosphatidate phosphatases[J].</article-title>
<source><italic>Chem Rev</italic></source>, <year>2012</year>, <volume>112</volume>(<issue>10</issue>): <fpage>5121</fpage>-<lpage>5146</lpage>.<pub-id pub-id-type="pmid">22742522</pub-id></mixed-citation></ref><ref id="b11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamal</surname><given-names>Z</given-names></name><name><surname>Martin</surname><given-names>A</given-names></name><name><surname>Gomez-Munoz</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Plasma membrane fractions from rat liver contain a phosphatidate phosphohydrolase distinct from that in the endoplasmic reticulum and cytosol[J].</article-title>
<source><italic>J Biol Chem</italic></source>, <year>1991</year>, <volume>266</volume>(<issue>5</issue>): <fpage>2988</fpage>-<lpage>2996</lpage>.<pub-id pub-id-type="pmid">1993672</pub-id></mixed-citation></ref><ref id="b12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brindley</surname><given-names>DN</given-names></name><name><surname>Waggoner</surname><given-names>DW</given-names></name></person-group>
<article-title>Mammalian lipid phosphate phosphohydrolases[J].</article-title>
<source><italic>J Biol Chem</italic></source>, <year>1998</year>, <volume>273</volume>(<issue>38</issue>): <fpage>24281</fpage>-<lpage>24284</lpage>.<pub-id pub-id-type="pmid">9733709</pub-id></mixed-citation></ref><ref id="b13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jasinska</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>QX</given-names></name><name><surname>Pilquil</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Lipid phosphate phosphohydrolase-1 degrades exogenous glycerolipid and sphingolipid phosphate esters[J].</article-title>
<source><italic>Biochem J</italic></source>, <year>1999</year>, <volume>340</volume> (<issue>Pt 3</issue>): <fpage>677</fpage>-<lpage>686</lpage>.<pub-id pub-id-type="pmid">10359651</pub-id></mixed-citation></ref><ref id="b14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bekele</surname><given-names>R</given-names></name><name><surname>Brindley</surname><given-names>DN</given-names></name></person-group>
<article-title>Role of autotaxin and lysophosphatidate in cancer progression and resistance to chemotherapy and radiotherapy[J].</article-title>
<source><italic>Clin Lipidol</italic></source>, <year>2012</year>, <volume>7</volume>: <fpage>313</fpage>-<lpage>328</lpage>.</mixed-citation></ref><ref id="b15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samadi</surname><given-names>N</given-names></name><name><surname>Bekele</surname><given-names>R</given-names></name><name><surname>Capatos</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance[J].</article-title>
<source><italic>Biochimie</italic></source>, <year>2011</year>, <volume>93</volume>(<issue>1</issue>): <fpage>61</fpage>-<lpage>70</lpage>.<pub-id pub-id-type="pmid">20709140</pub-id></mixed-citation></ref><ref id="b16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panchatcharam</surname><given-names>M</given-names></name><name><surname>Salous</surname><given-names>AK</given-names></name><name><surname>Brandon</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Mice with targeted inactivation of ppap2b in endothelial and hematopoietic cells display enhanced vascular inflammation and permeability[J].</article-title>
<source><italic>Arterioscler Thromb Vasc Biol</italic></source>, <year>2014</year>, <volume>34</volume>(<issue>4</issue>): <fpage>837</fpage>-<lpage>845</lpage>.<pub-id pub-id-type="pmid">24504738</pub-id></mixed-citation></ref><ref id="b17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>SS</given-names></name><name><surname>Mueller</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Arguing the case for the autotaxin-lysophosphatidic acid-lipid phosphate phosphatase 3-signaling nexus in the development and complications of atherosclerosis[J].</article-title>
<source><italic>Arterioscler Thromb Vasc Biol</italic></source>, <year>2014</year>, <volume>34</volume>(<issue>3</issue>): <fpage>479</fpage>-<lpage>486</lpage>.<pub-id pub-id-type="pmid">24482375</pub-id></mixed-citation></ref><ref id="b18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akira</surname><given-names>T</given-names></name><name><surname>Kengo</surname><given-names>H</given-names></name><name><surname>Kenji</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Involvement of lysophospholipase D in the production of lysophosphatidic acid in rat plasma[J].</article-title>
<source><italic>Biochim Biophys Acta</italic></source>, <year>1986</year>, <volume>875</volume>(<issue>1</issue>): <fpage>31</fpage>-<lpage>38</lpage>.<pub-id pub-id-type="pmid">3632787</pub-id></mixed-citation></ref><ref id="b19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stracke</surname><given-names>ML</given-names></name><name><surname>Krutzsch</surname><given-names>HC</given-names></name><name><surname>Unsworth</surname><given-names>EJ</given-names></name><etal/></person-group>
<article-title>Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein[J].</article-title>
<source><italic>J Biol Chem</italic></source>, <year>1992</year>, <volume>267</volume>(<issue>4</issue>): <fpage>2524</fpage>-<lpage>2529</lpage>.<pub-id pub-id-type="pmid">1733949</pub-id></mixed-citation></ref><ref id="b20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murata</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>HY</given-names></name><name><surname>Clair</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>cDNA cloning of the human tumor motility-stimulating protein, autotaxin, reveals a homology with phosphodiesterases[J].</article-title>
<source><italic>J Biol Chem</italic></source>, <year>1994</year>, <volume>269</volume>(<issue>48</issue>): <fpage>30479</fpage>-<lpage>30484</lpage>.<pub-id pub-id-type="pmid">7982964</pub-id></mixed-citation></ref><ref id="b21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckley</surname><given-names>MF</given-names></name><name><surname>Loveland</surname><given-names>KA</given-names></name><name><surname>McKinstry</surname><given-names>WJ</given-names></name><etal/></person-group>
<article-title>Plasma cell membrane glycoprotein PC-1. cDNA cloning of the human molecule, amino acid sequence, and chromosomal location[J].</article-title>
<source><italic>J Biol Chem</italic></source>, <year>1990</year>, <volume>265</volume>(<issue>29</issue>): <fpage>17506</fpage>-<lpage>17511</lpage>.<pub-id pub-id-type="pmid">2211644</pub-id></mixed-citation></ref><ref id="b22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funakoshi</surname><given-names>I</given-names></name><name><surname>Kato</surname><given-names>H</given-names></name><name><surname>Horie</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Molecular cloning of cDNAs for human fibroblast nucleotide pyrophosphatase[J].</article-title>
<source><italic>Arch Biochem Biophys</italic></source>, <year>1992</year>, <volume>295</volume>(<issue>1</issue>): <fpage>180</fpage>-<lpage>187</lpage>.<pub-id pub-id-type="pmid">1315502</pub-id></mixed-citation></ref><ref id="b23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawagoe</surname><given-names>H</given-names></name><name><surname>Soma</surname><given-names>O</given-names></name><name><surname>Goji</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Molecular cloning and chromosomal assignment of the human brain-type phosphodiesterase I/nucleotide pyrophosphatase gene (PDNP2)[J].</article-title>
<source><italic>Genomics</italic></source>, <year>1995</year>, <volume>30</volume>(<issue>2</issue>): <fpage>380</fpage>-<lpage>384</lpage>.<pub-id pub-id-type="pmid">8586446</pub-id></mixed-citation></ref><ref id="b24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umezu-Goto</surname><given-names>M</given-names></name><name><surname>Kishi</surname><given-names>Y</given-names></name><name><surname>Taira</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production[J].</article-title>
<source><italic>J Cell Biol</italic></source>, <year>2002</year>, <volume>158</volume>(<issue>2</issue>): <fpage>227</fpage>-<lpage>233</lpage>.<pub-id pub-id-type="pmid">12119361</pub-id></mixed-citation></ref><ref id="b25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokumura</surname><given-names>A</given-names></name><name><surname>Majima</surname><given-names>E</given-names></name><name><surname>Kariya</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase[J].</article-title>
<source><italic>J Biol Chem</italic></source>, <year>2002</year>, <volume>277</volume>(<issue>42</issue>): <fpage>39436</fpage>-<lpage>39442</lpage>.<pub-id pub-id-type="pmid">12176993</pub-id></mixed-citation></ref><ref id="b26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moolenaar</surname><given-names>WH</given-names></name></person-group>
<article-title>Lysophospholipids in the limelight: autotaxin takes center stage[J].</article-title>
<source><italic>J Cell Biol</italic></source>, <year>2002</year>, <volume>158</volume>(<issue>2</issue>): <fpage>197</fpage>-<lpage>199</lpage>.<pub-id pub-id-type="pmid">12135981</pub-id></mixed-citation></ref><ref id="b27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hama</surname><given-names>K</given-names></name><name><surname>Aoki</surname><given-names>J</given-names></name><name><surname>Fukaya</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1[J].</article-title>
<source><italic>J Biol Chem</italic></source>, <year>2004</year>, <volume>279</volume>(<issue>17</issue>): <fpage>17634</fpage>-<lpage>17639</lpage>.<pub-id pub-id-type="pmid">14744855</pub-id></mixed-citation></ref><ref id="b28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Meeteren</surname><given-names>LA</given-names></name><name><surname>Ruurs</surname><given-names>P</given-names></name><name><surname>Stortelers</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development[J].</article-title>
<source><italic>Mol Cell Biol</italic></source>, <year>2006</year>, <volume>26</volume>(<issue>13</issue>): <fpage>5015</fpage>-<lpage>5022</lpage>.<pub-id pub-id-type="pmid">16782887</pub-id></mixed-citation></ref><ref id="b29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koike</surname><given-names>S</given-names></name><name><surname>Keino-Masu</surname><given-names>K</given-names></name><name><surname>Masu</surname><given-names>M</given-names></name></person-group>
<article-title>Deficiency of autotaxin/lysophospholipase D results in head cavity formation in mouse embryos through the LPA receptor-Rho-ROCK pathway[J].</article-title>
<source><italic>Biochem Biophys Res Commun</italic></source>, <year>2010</year>, <volume>400</volume>(<issue>1</issue>): <fpage>66</fpage>-<lpage>71</lpage>.<pub-id pub-id-type="pmid">20692235</pub-id></mixed-citation></ref><ref id="b30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koike</surname><given-names>S</given-names></name><name><surname>Keino-Masu</surname><given-names>K</given-names></name><name><surname>Ohto</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Autotaxin/lysophospholipase D-mediated lysophosphatidic acid signaling is required to form distinctive large lysosomes in the visceral endoderm cells of the mouse yolk sac[J].</article-title>
<source><italic>J Biol Chem</italic></source>, <year>2009</year>, <volume>284</volume>(<issue>48</issue>): <fpage>33561</fpage>-<lpage>33570</lpage>.<pub-id pub-id-type="pmid">19808661</pub-id></mixed-citation></ref><ref id="b31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koike</surname><given-names>S</given-names></name><name><surname>Yutoh</surname><given-names>Y</given-names></name><name><surname>Keino-Masu</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Autotaxin is required for the cranial neural tube closure and establishment of the midbrain-hindbrain boundary during mouse development[J].</article-title>
<source><italic>Dev Dyn</italic></source>, <year>2011</year>, <volume>240</volume>(<issue>2</issue>): <fpage>413</fpage>-<lpage>421</lpage>.<pub-id pub-id-type="pmid">21246658</pub-id></mixed-citation></ref><ref id="b32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moolenaar</surname><given-names>WH</given-names></name><name><surname>Houben</surname><given-names>AJ</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><etal/></person-group>
<article-title>Autotaxin in embryonic development[J].</article-title>
<source><italic>Biochim Biophys Acta</italic></source>, <year>2013</year>, <volume>1831</volume>(<issue>1</issue>): <fpage>13</fpage>-<lpage>19</lpage>.<pub-id pub-id-type="pmid">23022664</pub-id></mixed-citation></ref><ref id="b33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Okudaira</surname><given-names>S</given-names></name><name><surname>Kishi</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid[J].</article-title>
<source><italic>J Biol Chem</italic></source>, <year>2006</year>, <volume>281</volume>(<issue>35</issue>): <fpage>25822</fpage>-<lpage>25830</lpage>.<pub-id pub-id-type="pmid">16829511</pub-id></mixed-citation></ref><ref id="b34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fotopoulou</surname><given-names>S</given-names></name><name><surname>Oikonomou</surname><given-names>N</given-names></name><name><surname>Grigorieva</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>ATX expression and LPA signalling are vital for the development of the nervous system[J].</article-title>
<source><italic>Dev Biol</italic></source>, <year>2010</year>, <volume>339</volume>(<issue>2</issue>): <fpage>451</fpage>-<lpage>464</lpage>.<pub-id pub-id-type="pmid">20079728</pub-id></mixed-citation></ref><ref id="b35"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yukiura</surname><given-names>H</given-names></name><name><surname>Hama</surname><given-names>K</given-names></name><name><surname>Nakanaga</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Autotaxin regulates vascular development via multiple lysophosphatidic acid (LPA) receptors in zebrafish[J].</article-title>
<source><italic>J Biol Chem</italic></source>, <year>2011</year>, <volume>286</volume>(<issue>51</issue>): <fpage>43972</fpage>-<lpage>43983</lpage>.<pub-id pub-id-type="pmid">21971049</pub-id></mixed-citation></ref><ref id="b36"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuelling</surname><given-names>LW</given-names></name><name><surname>Waggener</surname><given-names>CT</given-names></name><name><surname>Afshari</surname><given-names>FS</given-names></name><etal/></person-group>
<article-title>Autotaxin/ENPP2 regulates oligodendrocyte differentiation in vivo in the developing zebrafish hindbrain[J].</article-title>
<source><italic>Glia</italic></source>, <year>2012</year>, <volume>60</volume>(<issue>10</issue>): <fpage>1605</fpage>-<lpage>1618</lpage>.<pub-id pub-id-type="pmid">22821873</pub-id></mixed-citation></ref><ref id="b37"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>SL</given-names></name><name><surname>Yao</surname><given-names>WL</given-names></name><name><surname>Tsao</surname><given-names>KC</given-names></name><etal/></person-group>
<article-title>Autotaxin/Lpar3 signaling regulates Kupffer's vesicle formation and left-right asymmetry in zebrafish[J].</article-title>
<source><italic>Development</italic></source>, <year>2012</year>, <volume>139</volume>(<issue>23</issue>): <fpage>4439</fpage>-<lpage>4448</lpage>.<pub-id pub-id-type="pmid">23095890</pub-id></mixed-citation></ref><ref id="b38"><label>[38]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>HY</given-names></name><name><surname>Dong</surname><given-names>A</given-names></name><name><surname>Panchatcharam</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Lysophosphatidic acid signaling protects pulmonary vasculature from hypoxia-induced remodeling[J].</article-title>
<source><italic>Arterioscler Thromb Vasc Biol</italic></source>, <year>2012</year>, <volume>32</volume>(<issue>1</issue>): <fpage>24</fpage>-<lpage>32</lpage>.<pub-id pub-id-type="pmid">22015657</pub-id></mixed-citation></ref><ref id="b39"><label>[39]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brindley</surname><given-names>DN</given-names></name></person-group>
<article-title>Lipid phosphate phosphatases and related proteins: signaling functions in development, cell division, and cancer[J].</article-title>
<source><italic>J Cell Biochem</italic></source>, <year>2004</year>, <volume>92</volume>(<issue>5</issue>): <fpage>900</fpage>-<lpage>912</lpage>.<pub-id pub-id-type="pmid">15258914</pub-id></mixed-citation></ref><ref id="b40"><label>[40]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazereeuw-Hautier</surname><given-names>J</given-names></name><name><surname>Gres</surname><given-names>S</given-names></name><name><surname>Fanguin</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Production of lysophosphatidic acid in blister fluid: involvement of a lysophospholipase D activity[J].</article-title>
<source><italic>J Invest Dermatol</italic></source>, <year>2005</year>, <volume>125</volume>(<issue>3</issue>): <fpage>421</fpage>-<lpage>427</lpage>.<pub-id pub-id-type="pmid">16117781</pub-id></mixed-citation></ref><ref id="b41"><label>[41]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokumura</surname><given-names>A</given-names></name><name><surname>Taira</surname><given-names>S</given-names></name><name><surname>Kikuchi</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Lysophospholipids and lysophospholipase D in rabbit aqueous humor following corneal injury[J].</article-title>
<source><italic>Prostaglandins Other Lipid Mediat</italic></source>, <year>2012</year>, <volume>97</volume>(<issue>3-4</issue>): <fpage>83</fpage>-<lpage>89</lpage>.<pub-id pub-id-type="pmid">22281604</pub-id></mixed-citation></ref><ref id="b42"><label>[42]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grisanti</surname><given-names>L</given-names></name><name><surname>Rezza</surname><given-names>A</given-names></name><name><surname>Clavel</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Enpp2/Autotaxin in dermal papilla precursors is dispensable for hair follicle morphogenesis[J].</article-title>
<source><italic>J Invest Dermatol</italic></source>, <year>2013</year>, <volume>133</volume>(<issue>10</issue>): <fpage>2332</fpage>-<lpage>2339</lpage>.<pub-id pub-id-type="pmid">23677168</pub-id></mixed-citation></ref><ref id="b43"><label>[43]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mebarek</surname><given-names>S</given-names></name><name><surname>Abousalham</surname><given-names>A</given-names></name><name><surname>Magne</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Phospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizations[J].</article-title>
<source><italic>Int J Mol Sci</italic></source>, <year>2013</year>, <volume>14</volume>(<issue>3</issue>): <fpage>5036</fpage>-<lpage>5129</lpage>.<pub-id pub-id-type="pmid">23455471</pub-id></mixed-citation></ref><ref id="b44"><label>[44]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evseenko</surname><given-names>D</given-names></name><name><surname>Latour</surname><given-names>B</given-names></name><name><surname>Richardson</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Lysophosphatidic acid mediates myeloid differentiation within the human bone marrow microenvironment[J].</article-title>
<source><italic>PLoS One</italic></source>, <year>2013</year>, <volume>8</volume>(<issue>5</issue>): <fpage>e63718</fpage>.<pub-id pub-id-type="pmid">23696850</pub-id></mixed-citation></ref><ref id="b45"><label>[45]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masuda</surname><given-names>K</given-names></name><name><surname>Haruta</surname><given-names>S</given-names></name><name><surname>Orino</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Autotaxin as a novel, tissue-remodeling-related factor in regressing corpora lutea of cycling rats[J].</article-title>
<source><italic>FEBS J</italic></source>, <year>2013</year>, <volume>280</volume>: <fpage>6600</fpage>-<lpage>6612</lpage>.<pub-id pub-id-type="pmid">24128332</pub-id></mixed-citation></ref><ref id="b46"><label>[46]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awada</surname><given-names>R</given-names></name><name><surname>Rondeau</surname><given-names>P</given-names></name><name><surname>Gres</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Autotaxin protects microglial cells against oxidative stress[J].</article-title>
<source><italic>Free Radic Biol Med</italic></source>, <year>2012</year>, <volume>52</volume>(<issue>2</issue>): <fpage>516</fpage>-<lpage>526</lpage>.<pub-id pub-id-type="pmid">22155714</pub-id></mixed-citation></ref><ref id="b47"><label>[47]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awada</surname><given-names>R</given-names></name><name><surname>Saulnier-Blache</surname><given-names>JS</given-names></name><name><surname>Gres</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Autotaxin downregulates LPS-induced microglia activation and proinflammatory cytokines production[J].</article-title>
<source><italic>J Cell Biochem</italic></source>, <year>2014</year>, <volume>115</volume>(<issue>12</issue>): <fpage>2123</fpage>-<lpage>2132</lpage>.<pub-id pub-id-type="pmid">25053164</pub-id></mixed-citation></ref><ref id="b48"><label>[48]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umemoto</surname><given-names>E</given-names></name><name><surname>Hayasaka</surname><given-names>H</given-names></name><name><surname>Bai</surname><given-names>Z</given-names></name><etal/></person-group>
<article-title>Novel regulators of lymphocyte trafficking across high endothelial venules[J].</article-title>
<source><italic>Crit Rev Immunol</italic></source>, <year>2011</year>, <volume>31</volume>(<issue>2</issue>): <fpage>147</fpage>-<lpage>169</lpage>.<pub-id pub-id-type="pmid">21542791</pub-id></mixed-citation></ref><ref id="b49"><label>[49]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>Z</given-names></name><name><surname>Cai</surname><given-names>L</given-names></name><name><surname>Umemoto</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Constitutive lymphocyte transmigration across the basal lamina of high endothelial venules is regulated by the autotaxin/lysophosphatidic acid axis[J].</article-title>
<source><italic>J Immunol</italic></source>, <year>2013</year>, <volume>190</volume>(<issue>5</issue>): <fpage>2036</fpage>-<lpage>2048</lpage>.<pub-id pub-id-type="pmid">23365076</pub-id></mixed-citation></ref><ref id="b50"><label>[50]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name><name><surname>Krummel</surname><given-names>MF</given-names></name><etal/></person-group>
<article-title>Autotaxin through lysophosphatidic acid stimulates polarization, motility, and transendothelial migration of naive T cells[J].</article-title>
<source><italic>J Immunol</italic></source>, <year>2012</year>, <volume>189</volume>(<issue>8</issue>): <fpage>3914</fpage>-<lpage>3924</lpage>.<pub-id pub-id-type="pmid">22962684</pub-id></mixed-citation></ref><ref id="b51"><label>[51]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knowlden</surname><given-names>S</given-names></name><name><surname>Georas</surname><given-names>SN</given-names></name></person-group>
<article-title>The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation[J].</article-title>
<source><italic>J Immunol</italic></source>, <year>2014</year>, <volume>192</volume>(<issue>3</issue>): <fpage>851</fpage>-<lpage>857</lpage>.<pub-id pub-id-type="pmid">24443508</pub-id></mixed-citation></ref><ref id="b52"><label>[52]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakasaki</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Okudaira</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions[J].</article-title>
<source><italic>Am J Pathol</italic></source>, <year>2008</year>, <volume>173</volume>(<issue>5</issue>): <fpage>1566</fpage>-<lpage>1576</lpage>.<pub-id pub-id-type="pmid">18818380</pub-id></mixed-citation></ref><ref id="b53"><label>[53]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Meeteren</surname><given-names>LA</given-names></name><name><surname>Moolenaar</surname><given-names>WH</given-names></name></person-group>
<article-title>Regulation and biological activities of the autotaxin-LPA axis[J].</article-title>
<source><italic>Prog Lipid Res</italic></source>, <year>2007</year>, <volume>46</volume>(<issue>2</issue>): <fpage>145</fpage>-<lpage>160</lpage>.<pub-id pub-id-type="pmid">17459484</pub-id></mixed-citation></ref><ref id="b54"><label>[54]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Budd</surname><given-names>DC</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name></person-group>
<article-title>Development of lysophosphatidic acid pathway modulators as therapies for fibrosis[J].</article-title>
<source><italic>Future Med Chem</italic></source>, <year>2013</year>, <volume>5</volume>(<issue>16</issue>): <fpage>1935</fpage>-<lpage>1952</lpage>.<pub-id pub-id-type="pmid">24175745</pub-id></mixed-citation></ref><ref id="b55"><label>[55]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benesch</surname><given-names>MGK</given-names></name><name><surname>Zhao</surname><given-names>YY</given-names></name><name><surname>Curtis</surname><given-names>JM</given-names></name><etal/></person-group>
<article-title>Regulation of autotaxin expression by lysophosphatidate and sphingosine 1-phosphate[J].</article-title>
<source><italic>J Lipid Res</italic></source>, <year>2015</year>
<pub-id pub-id-type="doi">10.1194/jlr.M057661</pub-id>.</mixed-citation></ref><ref id="b56"><label>[56]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benesch</surname><given-names>MGK</given-names></name><name><surname>Ko</surname><given-names>YM</given-names></name><name><surname>McMullen</surname><given-names>TPW</given-names></name><etal/></person-group>
<article-title>Autotaxin in the crosshairs: Taking aim at cancer and other inflammatory conditions[J].</article-title>
<source><italic>FEBS Lett</italic></source>, <year>2014</year>,<volume>588</volume>(<issue>16</issue>): <fpage>2712</fpage>-<lpage>2727</lpage>.<pub-id pub-id-type="pmid">24560789</pub-id></mixed-citation></ref><ref id="b57"><label>[57]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bollen</surname><given-names>M</given-names></name><name><surname>Gijsbers</surname><given-names>R</given-names></name><name><surname>Ceulemans</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Nucleotide pyrophosphatases/phosphodiesterases on the move[J].</article-title>
<source><italic>Crit Rev Biochem Mol Biol</italic></source>, <year>2000</year>, <volume>35</volume>(<issue>6</issue>): <fpage>393</fpage>-<lpage>432</lpage>.<pub-id pub-id-type="pmid">11202013</pub-id></mixed-citation></ref><ref id="b58"><label>[58]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debies</surname><given-names>MT</given-names></name><name><surname>Welch</surname><given-names>DR</given-names></name></person-group>
<article-title>Genetic basis of human breast cancer metastasis[J].</article-title>
<source><italic>J Mammary Gland Biol Neoplasia</italic></source>, <year>2001</year>, <volume>6</volume>(<issue>4</issue>): <fpage>441</fpage>-<lpage>451</lpage>.<pub-id pub-id-type="pmid">12013533</pub-id></mixed-citation></ref><ref id="b59"><label>[59]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moolenaar</surname><given-names>WH</given-names></name><name><surname>van Meeteren</surname><given-names>LA</given-names></name><name><surname>Giepmans</surname><given-names>BN</given-names></name></person-group>
<article-title>The ins and outs of lysophosphatidic acid signaling[J].</article-title>
<source><italic>Bioessays</italic></source>, <year>2004</year>, <volume>26</volume>(<issue>8</issue>): <fpage>870</fpage>-<lpage>881</lpage>.<pub-id pub-id-type="pmid">15273989</pub-id></mixed-citation></ref><ref id="b60"><label>[60]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gendaszewska-Darmach</surname><given-names>E</given-names></name></person-group>
<article-title>Lysophosphatidic acids, cyclic phosphatidic acids and autotaxin as promising targets in therapies of cancer and other diseases[J].</article-title>
<source><italic>Acta Biochim Pol</italic></source>, <year>2008</year>, <volume>55</volume>(<issue>2</issue>): <fpage>227</fpage>-<lpage>240</lpage>.<pub-id pub-id-type="pmid">18560605</pub-id></mixed-citation></ref><ref id="b61"><label>[61]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Murph</surname><given-names>M</given-names></name><name><surname>Panupinthu</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>ATX-LPA receptor axis in inflammation and cancer[J].</article-title>
<source><italic>Cell Cycle</italic></source>, <year>2009</year>, <volume>8</volume>(<issue>22</issue>): <fpage>3695</fpage>-<lpage>3701</lpage>.<pub-id pub-id-type="pmid">19855166</pub-id></mixed-citation></ref><ref id="b62"><label>[62]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panupinthu</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>HY</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name></person-group>
<article-title>Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression[J].</article-title>
<source><italic>Br J Cancer</italic></source>, <year>2010</year>, <volume>102</volume>(<issue>6</issue>): <fpage>941</fpage>-<lpage>946</lpage>.<pub-id pub-id-type="pmid">20234370</pub-id></mixed-citation></ref><ref id="b63"><label>[63]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houben</surname><given-names>AJ</given-names></name><name><surname>Moolenaar</surname><given-names>WH</given-names></name></person-group>
<article-title>Autotaxin and LPA receptor signaling in cancer[J].</article-title>
<source><italic>Cancer Metastasis Rev</italic></source>, <year>2011</year>, <volume>30</volume>(<issue>3-4</issue>): <fpage>557</fpage>-<lpage>565</lpage>.<pub-id pub-id-type="pmid">22002750</pub-id></mixed-citation></ref><ref id="b64"><label>[64]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotoh</surname><given-names>M</given-names></name><name><surname>Fujiwara</surname><given-names>Y</given-names></name><name><surname>Yue</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis[J].</article-title>
<source><italic>Biochem Soc Trans</italic></source>, <year>2012</year>, <volume>40</volume>(<issue>1</issue>): <fpage>31</fpage>-<lpage>36</lpage>.<pub-id pub-id-type="pmid">22260662</pub-id></mixed-citation></ref><ref id="b65"><label>[65]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peyruchaud</surname><given-names>O</given-names></name><name><surname>Leblanc</surname><given-names>R</given-names></name><name><surname>David</surname><given-names>M</given-names></name></person-group>
<article-title>Pleiotropic activity of lysophosphatidic acid in bone metastasis[J].</article-title>
<source><italic>Biochim Biophys Acta</italic></source>, <year>2013</year>, <volume>1831</volume>(<issue>1</issue>): <fpage>99</fpage>-<lpage>104</lpage>.<pub-id pub-id-type="pmid">22710393</pub-id></mixed-citation></ref><ref id="b66"><label>[66]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>So</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>FQ</given-names></name><name><surname>Navari</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2)[J].</article-title>
<source><italic>Gynecol Oncol</italic></source>, <year>2005</year>, <volume>97</volume>(<issue>3</issue>): <fpage>870</fpage>-<lpage>878</lpage>.<pub-id pub-id-type="pmid">15919106</pub-id></mixed-citation></ref><ref id="b67"><label>[67]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murph</surname><given-names>MM</given-names></name><name><surname>Hurst-Kennedy</surname><given-names>J</given-names></name><name><surname>Newton</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>Lysophosphatidic acid decreases the nuclear localization and cellular abundance of the p53 tumor suppressor in A549 lung carcinoma cells[J].</article-title>
<source><italic>Mol Cancer Res</italic></source>, <year>2007</year>, <volume>5</volume>(<issue>11</issue>): <fpage>1201</fpage>-<lpage>1211</lpage>.<pub-id pub-id-type="pmid">18025263</pub-id></mixed-citation></ref><ref id="b68"><label>[68]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samadi</surname><given-names>N</given-names></name><name><surname>Bekele</surname><given-names>RT</given-names></name><name><surname>Goping</surname><given-names>IS</given-names></name><etal/></person-group>
<article-title>Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest[J].</article-title>
<source><italic>PLoS One</italic></source>, <year>2011</year>, <volume>6</volume>(<issue>5</issue>): <fpage>e20608</fpage>.<pub-id pub-id-type="pmid">21647386</pub-id></mixed-citation></ref><ref id="b69"><label>[69]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Requirement of Osteo-pontin in migration and the protection against Taxol-induced apoptosis via ATX-LPA axis in SGC7901 cells[J].</article-title>
<source><italic>BMC Cell Biol</italic></source>, <year>2011</year>, <volume>12</volume>(<issue>1</issue>): <fpage>11</fpage>.<pub-id pub-id-type="pmid">21406114</pub-id></mixed-citation></ref><ref id="b70"><label>[70]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vidot</surname><given-names>S</given-names></name><name><surname>Witham</surname><given-names>J</given-names></name><name><surname>Agarwal</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells[J].</article-title>
<source><italic>Cell Signal</italic></source>, <year>2010</year>, <volume>22</volume>(<issue>6</issue>): <fpage>926</fpage>-<lpage>935</lpage>.<pub-id pub-id-type="pmid">20100569</pub-id></mixed-citation></ref><ref id="b71"><label>[71]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Shuyu</surname><given-names>E</given-names></name><name><surname>Tsukahara</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury[J].</article-title>
<source><italic>Gastroenterology</italic></source>, <year>2007</year>, <volume>132</volume>(<issue>5</issue>): <fpage>1834</fpage>-<lpage>1851</lpage>.<pub-id pub-id-type="pmid">17484878</pub-id></mixed-citation></ref><ref id="b72"><label>[72]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Umezu-Goto</surname><given-names>M</given-names></name><name><surname>Murph</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases[J].</article-title>
<source><italic>Cancer Cell</italic></source>, <year>2009</year>, <volume>15</volume>(<issue>6</issue>): <fpage>539</fpage>-<lpage>550</lpage>.<pub-id pub-id-type="pmid">19477432</pub-id></mixed-citation></ref><ref id="b73"><label>[73]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Euer</surname><given-names>N</given-names></name><name><surname>Schwirzke</surname><given-names>M</given-names></name><name><surname>Evtimova</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>Identification of genes associated with metastasis of mammary carcinoma in metastatic versus non-metastatic cell lines[J].</article-title>
<source><italic>Anticancer Res</italic></source>, <year>2002</year>, <volume>22</volume>(<issue>2A</issue>): <fpage>733</fpage>-<lpage>740</lpage>.<pub-id pub-id-type="pmid">12014644</pub-id></mixed-citation></ref><ref id="b74"><label>[74]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>St-Coeur</surname><given-names>PD</given-names></name><name><surname>Ferguson</surname><given-names>D</given-names></name><name><surname>Morin</surname><given-names>P</given-names><suffix>Jr.</suffix></name><etal/></person-group>
<article-title>PF-8380 and closely related analogs: synthesis and structure-activity relationship towards autotaxin inhibition and glioma cell viability[J].</article-title>
<source><italic>Arch Pharm</italic></source>, <year>2013</year>, <volume>346</volume>(<issue>2</issue>): <fpage>91</fpage>-<lpage>97</lpage>.</mixed-citation></ref><ref id="b75"><label>[75]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popnikolov</surname><given-names>NK</given-names></name><name><surname>Dalwadi</surname><given-names>BH</given-names></name><name><surname>Thomas</surname><given-names>JD</given-names></name><etal/></person-group>
<article-title>Association of autotaxin and lysophosphatidic acid receptor 3 with aggressiveness of human breast carcinoma[J].</article-title>
<source><italic>Tumour Biol</italic></source>, <year>2012</year>, <volume>33</volume>(<issue>6</issue>): <fpage>2237</fpage>-<lpage>2243</lpage>.<pub-id pub-id-type="pmid">22922883</pub-id></mixed-citation></ref><ref id="b76"><label>[76]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benesch</surname><given-names>MGK</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Maeda</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice[J].</article-title>
<source><italic>FASEB J</italic></source>, <year>2014</year>, <volume>28</volume>(<issue>6</issue>): <fpage>2655</fpage>-<lpage>2666</lpage>.<pub-id pub-id-type="pmid">24599971</pub-id></mixed-citation></ref><ref id="b77"><label>[77]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leblanc</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>SC</given-names></name><name><surname>David</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Interaction of platelet-derived autotaxin with tumor integrin alphaVbeta3 controls metastasis of breast cancer cells to bone[J].</article-title>
<source><italic>Blood</italic></source>, <year>2014</year>, <volume>124</volume>(<issue>20</issue>): <fpage>3141</fpage>-<lpage>3150</lpage>.<pub-id pub-id-type="pmid">25277122</pub-id></mixed-citation></ref><ref id="b78"><label>[78]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brindley</surname><given-names>DN</given-names></name><name><surname>Benesch</surname><given-names>MGK</given-names></name><name><surname>Murph</surname><given-names>MM</given-names></name></person-group>
<article-title>Autotaxin - An Enzymatic Augmenter of Malignant Progression Linked to Inflammation.</article-title>
<source><italic>Melanoma - Current Clinical Management and Future Therapeutics</italic>: InTech Open.</source>
<year>2015</year>: <fpage>297</fpage>-<lpage>324</lpage>. 2<pub-id pub-id-type="doi">10.5772/59013</pub-id>.</mixed-citation></ref><ref id="b79"><label>[79]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbayianni</surname><given-names>E</given-names></name><name><surname>Kaffe</surname><given-names>E</given-names></name><name><surname>Aidinis</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer[J].</article-title>
<source><italic>Prog Lipid Res</italic></source>, <year>2015</year>, <volume>58</volume>: <fpage>76</fpage>-<lpage>96</lpage>.<pub-id pub-id-type="pmid">25704398</pub-id></mixed-citation></ref><ref id="b80"><label>[80]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname><given-names>J</given-names></name><name><surname>Hla</surname><given-names>T</given-names></name><name><surname>Lynch</surname><given-names>KR</given-names></name><etal/></person-group>
<article-title>International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature[J].</article-title>
<source><italic>Pharmacol Rev</italic></source>, <year>2010</year>, <volume>62</volume>(<issue>4</issue>): <fpage>579</fpage>-<lpage>587</lpage>.<pub-id pub-id-type="pmid">21079037</pub-id></mixed-citation></ref><ref id="b81"><label>[81]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hecht</surname><given-names>JH</given-names></name><name><surname>Weiner</surname><given-names>JA</given-names></name><name><surname>Post</surname><given-names>SR</given-names></name><etal/></person-group>
<article-title>Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex[J].</article-title>
<source><italic>J Cell Biol</italic></source>, <year>1996</year>, <volume>135</volume>(<issue>4</issue>): <fpage>1071</fpage>-<lpage>1083</lpage>.<pub-id pub-id-type="pmid">8922387</pub-id></mixed-citation></ref><ref id="b82"><label>[82]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>S</given-names></name><name><surname>Bleu</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids[J].</article-title>
<source><italic>FEBS Lett</italic></source>, <year>1997</year>, <volume>417</volume>(<issue>3</issue>): <fpage>279</fpage>-<lpage>282</lpage>.<pub-id pub-id-type="pmid">9409733</pub-id></mixed-citation></ref><ref id="b83"><label>[83]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>S</given-names></name><name><surname>Bleu</surname><given-names>T</given-names></name><name><surname>Hallmark</surname><given-names>OG</given-names></name><etal/></person-group>
<article-title>Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid[J].</article-title>
<source><italic>J Biol Chem</italic></source>, <year>1998</year>, <volume>273</volume>(<issue>14</issue>): <fpage>7906</fpage>-<lpage>7910</lpage>.<pub-id pub-id-type="pmid">9525886</pub-id></mixed-citation></ref><ref id="b84"><label>[84]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandoh</surname><given-names>K</given-names></name><name><surname>Aoki</surname><given-names>J</given-names></name><name><surname>Hosono</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid[J].</article-title>
<source><italic>J Biol Chem</italic></source>, <year>1999</year>, <volume>274</volume>(<issue>39</issue>): <fpage>27776</fpage>-<lpage>27785</lpage>.<pub-id pub-id-type="pmid">10488122</pub-id></mixed-citation></ref><ref id="b85"><label>[85]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Skinner</surname><given-names>MK</given-names></name><name><surname>Kennedy</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Age-Dependent Loss of Sperm Production in Mice via Impaired Lysophosphatidic Acid Signaling[J].</article-title>
<source><italic>Biol Reprod</italic></source>, <year>2008</year>, <volume>79</volume>(<issue>2</issue>): <fpage>328</fpage>-<lpage>336</lpage>.<pub-id pub-id-type="pmid">18448840</pub-id></mixed-citation></ref><ref id="b86"><label>[86]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Contos</surname><given-names>JJA</given-names></name><name><surname>Ishii</surname><given-names>I</given-names></name><name><surname>Fukushima</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Characterization of lpa2 (Edg4) and lpa1/lpa2 (Edg2/Edg4) Lysophosphatidic Acid Receptor Knockout Mice: Signaling Deficits without Obvious Phenotypic Abnormality Attributable to lpa2[J].</article-title>
<source><italic>Mol Cell Biol</italic></source>, <year>2002</year>, <volume>22</volume>(<issue>19</issue>): <fpage>6921</fpage>-<lpage>6929</lpage>.<pub-id pub-id-type="pmid">12215548</pub-id></mixed-citation></ref><ref id="b87"><label>[87]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Contos</surname><given-names>JJ</given-names></name><name><surname>Fukushima</surname><given-names>N</given-names></name><name><surname>Weiner</surname><given-names>JA</given-names></name><etal/></person-group>
<article-title>Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior[J].</article-title>
<source><italic>Proc Natl Acad Sci U S A</italic></source>, <year>2000</year>, <volume>97</volume>(<issue>24</issue>): <fpage>13384</fpage>-<lpage>13389</lpage>.<pub-id pub-id-type="pmid">11087877</pub-id></mixed-citation></ref><ref id="b88"><label>[88]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Hama</surname><given-names>K</given-names></name><name><surname>Contos</surname><given-names>JJ</given-names></name><etal/></person-group>
<article-title>LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing[J].</article-title>
<source><italic>Nature</italic></source>, <year>2005</year>, <volume>435</volume>(<issue>7038</issue>): <fpage>104</fpage>-<lpage>108</lpage>.<pub-id pub-id-type="pmid">15875025</pub-id></mixed-citation></ref><ref id="b89"><label>[89]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Contos</surname><given-names>JJ</given-names></name><name><surname>Ishii</surname><given-names>I</given-names></name><name><surname>Fukushima</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2)[J].</article-title>
<source><italic>Mol Cell Biol</italic></source>, <year>2002</year>, <volume>22</volume>(<issue>19</issue>): <fpage>6921</fpage>-<lpage>6929</lpage>.<pub-id pub-id-type="pmid">12215548</pub-id></mixed-citation></ref><ref id="b90"><label>[90]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yung</surname><given-names>YC</given-names></name><name><surname>Stoddard</surname><given-names>NC</given-names></name><name><surname>Chun</surname><given-names>J</given-names></name></person-group>
<article-title>LPA receptor signaling: pharmacology, physiology, and pathophysiology[J].</article-title>
<source><italic>J Lipid Res</italic></source>, <year>2014</year>, <volume>55</volume>(<issue>7</issue>): <fpage>1192</fpage>-<lpage>1214</lpage>.<pub-id pub-id-type="pmid">24643338</pub-id></mixed-citation></ref><ref id="b91"><label>[91]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohuchi</surname><given-names>H</given-names></name><name><surname>Hamada</surname><given-names>A</given-names></name><name><surname>Matsuda</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Expression patterns of the lysophospholipid receptor genes during mouse early development[J].</article-title>
<source><italic>Dev Dyn</italic></source>, <year>2008</year>, <volume>237</volume>(<issue>11</issue>): <fpage>3280</fpage>-<lpage>3294</lpage>.<pub-id pub-id-type="pmid">18924241</pub-id></mixed-citation></ref><ref id="b92"><label>[92]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>JW</given-names></name><name><surname>Herr</surname><given-names>DR</given-names></name><name><surname>Noguchi</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>LPA receptors: sub-types and biological actions[J].</article-title>
<source><italic>Annu Rev Pharmacol Toxicol</italic></source>, <year>2010</year>, <volume>50</volume>: <fpage>157</fpage>-<lpage>186</lpage>.<pub-id pub-id-type="pmid">20055701</pub-id></mixed-citation></ref><ref id="b93"><label>[93]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer zu Heringdorf</surname><given-names>D</given-names></name><name><surname>Jakobs</surname><given-names>KH</given-names></name></person-group>
<article-title>Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism[J].</article-title>
<source><italic>Biochim Biophys Acta</italic></source>, <year>2007</year>, <volume>1768</volume>(<issue>4</issue>): <fpage>923</fpage>-<lpage>940</lpage>.<pub-id pub-id-type="pmid">17078925</pub-id></mixed-citation></ref><ref id="b94"><label>[94]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundequist</surname><given-names>A</given-names></name><name><surname>Boyce</surname><given-names>JA</given-names></name></person-group>
<article-title>LPA5 is abundantly expressed by human mast cells and important for lysophosphatidic acid induced MIP-1beta release[J].</article-title>
<source><italic>PLoS One</italic></source>, <year>2011</year>, <volume>6</volume>(<issue>3</issue>): <fpage>e18192</fpage>.<pub-id pub-id-type="pmid">21464938</pub-id></mixed-citation></ref><ref id="b95"><label>[95]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Z</given-names></name><name><surname>Cheng</surname><given-names>CT</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Role of LPA4/p2y9/GPR23 in negative regulation of cell motility[J].</article-title>
<source><italic>Mol Biol Cell</italic></source>, <year>2008</year>, <volume>19</volume>(<issue>12</issue>): <fpage>5435</fpage>-<lpage>5445</lpage>.<pub-id pub-id-type="pmid">18843048</pub-id></mixed-citation></ref><ref id="b96"><label>[96]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>ME</given-names></name><name><surname>Rivera</surname><given-names>RR</given-names></name><name><surname>Chun</surname><given-names>J</given-names></name></person-group>
<article-title>Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain[J].</article-title>
<source><italic>J Biol Chem</italic></source>, <year>2012</year>, <volume>287</volume>(<issue>21</issue>): <fpage>17608</fpage>-<lpage>17617</lpage>.<pub-id pub-id-type="pmid">22461625</pub-id></mixed-citation></ref><ref id="b97"><label>[97]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasternack</surname><given-names>SM</given-names></name><name><surname>von Kugelgen</surname><given-names>I</given-names></name><name><surname>Al Aboud</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth[J].</article-title>
<source><italic>Nat Genet</italic></source>, <year>2008</year>, <volume>40</volume>(<issue>3</issue>): <fpage>329</fpage>-<lpage>334</lpage>.<pub-id pub-id-type="pmid">18297070</pub-id></mixed-citation></ref><ref id="b98"><label>[98]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Hallden</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>P2Y5 is a G(alpha)i, G(alpha)12/13 G protein-coupled receptor activated by lysophosphatidic acid that reduces intestinal cell adhesion[J].</article-title>
<source><italic>Am J Physiol Gastrointest Liver Physiol</italic></source>, <year>2009</year>, <volume>297</volume>(<issue>4</issue>): <fpage>G641</fpage>-<lpage>654</lpage>.<pub-id pub-id-type="pmid">19679818</pub-id></mixed-citation></ref><ref id="b99"><label>[99]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furui</surname><given-names>T</given-names></name><name><surname>LaPushin</surname><given-names>R</given-names></name><name><surname>Mao</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner[J].</article-title>
<source><italic>Clin Cancer Res</italic></source>, <year>1999</year>, <volume>5</volume>(<issue>12</issue>): <fpage>4308</fpage>-<lpage>4318</lpage>.<pub-id pub-id-type="pmid">10632375</pub-id></mixed-citation></ref><ref id="b100"><label>[100]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pustilnik</surname><given-names>TB</given-names></name><name><surname>Estrella</surname><given-names>V</given-names></name><name><surname>Wiener</surname><given-names>JR</given-names></name><etal/></person-group>
<article-title>Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells[J].</article-title>
<source><italic>Clin Cancer Res</italic></source>, <year>1999</year>, <volume>5</volume>(<issue>11</issue>): <fpage>3704</fpage>-<lpage>3710</lpage>.<pub-id pub-id-type="pmid">10589790</pub-id></mixed-citation></ref><ref id="b101"><label>[101]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shida</surname><given-names>D</given-names></name><name><surname>Kitayama</surname><given-names>J</given-names></name><name><surname>Yamaguchi</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1[J].</article-title>
<source><italic>Cancer Res</italic></source>, <year>2003</year>, <volume>63</volume>(<issue>7</issue>): <fpage>1706</fpage>-<lpage>1711</lpage>.<pub-id pub-id-type="pmid">12670925</pub-id></mixed-citation></ref><ref id="b102"><label>[102]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulte</surname><given-names>KM</given-names></name><name><surname>Beyer</surname><given-names>A</given-names></name><name><surname>Kohrer</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: over-expression of the high-affinity receptor edg4 in differentiated thyroid cancer[J].</article-title>
<source><italic>Int J Cancer</italic></source>, <year>2001</year>, <volume>92</volume>(<issue>2</issue>): <fpage>249</fpage>-<lpage>256</lpage>.<pub-id pub-id-type="pmid">11291053</pub-id></mixed-citation></ref><ref id="b103"><label>[103]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitayama</surname><given-names>J</given-names></name><name><surname>Shida</surname><given-names>D</given-names></name><name><surname>Sako</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma[J].</article-title>
<source><italic>Breast Cancer Res</italic></source>, <year>2004</year>, <volume>6</volume>(<issue>6</issue>): <fpage>R640</fpage>-<lpage>646</lpage>.<pub-id pub-id-type="pmid">15535846</pub-id></mixed-citation></ref><ref id="b104"><label>[104]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shida</surname><given-names>D</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Aoki</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer[J].</article-title>
<source><italic>Lab Invest</italic></source>, <year>2004</year>, <volume>84</volume>(<issue>10</issue>): <fpage>1352</fpage>-<lpage>1362</lpage>.<pub-id pub-id-type="pmid">15220934</pub-id></mixed-citation></ref><ref id="b105"><label>[105]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okabe</surname><given-names>K</given-names></name><name><surname>Hayashi</surname><given-names>M</given-names></name><name><surname>Kato</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Lysophosphatidic acid receptor-3 increases tumorigenicity and aggressiveness of rat hepatoma RH7777 cells[J].</article-title>
<source><italic>Mol Carcinog</italic></source>, <year>2013</year>, <volume>52</volume>(<issue>4</issue>): <fpage>247</fpage>-<lpage>254</lpage>.<pub-id pub-id-type="pmid">22161812</pub-id></mixed-citation></ref><ref id="b106"><label>[106]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okabe</surname><given-names>K</given-names></name><name><surname>Hayashi</surname><given-names>M</given-names></name><name><surname>Yamawaki</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Possible involvement of lysophosphatidic acid receptor-5 gene in the acquisition of growth advantage of rat tumor cells[J].</article-title>
<source><italic>Mol Carcinog</italic></source>, <year>2011</year>, <volume>50</volume>(<issue>8</issue>): <fpage>635</fpage>-<lpage>642</lpage>.<pub-id pub-id-type="pmid">21374735</pub-id></mixed-citation></ref><ref id="b107"><label>[107]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SC</given-names></name><name><surname>Fujiwara</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Autotaxin and LPA1 and LPA5 Receptors Exert Disparate Functions in Tumor Cells versus the Host Tissue Microenvironment in Melanoma Invasion and Metastasis[J].</article-title>
<source><italic>Mol Cancer Res</italic></source>, <year>2015</year>, <volume>13</volume>(<issue>1</issue>): <fpage>174</fpage>-<lpage>185</lpage>.<pub-id pub-id-type="pmid">25158955</pub-id></mixed-citation></ref><ref id="b108"><label>[108]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kihara</surname><given-names>Y</given-names></name><name><surname>Mizuno</surname><given-names>H</given-names></name><name><surname>Chun</surname><given-names>J</given-names></name></person-group>
<article-title>Lysophospholipid receptors in drug discovery[J].</article-title>
<source><italic>Exp Cell Res</italic></source>, <year>2014</year>
<pub-id pub-id-type="doi">10.1016/j.yexcr.2014.1011.1020</pub-id>.</mixed-citation></ref><ref id="b109"><label>[109]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoddard</surname><given-names>NC</given-names></name><name><surname>Chun</surname><given-names>J</given-names></name></person-group>
<article-title>Promising pharmacological directions in the world of lysophosphatidic Acid signaling[J].</article-title>
<source><italic>Biomol Ther (Seoul)</italic></source>, <year>2015</year>, <volume>23</volume>(<issue>1</issue>): <fpage>1</fpage>-<lpage>11</lpage>.<pub-id pub-id-type="pmid">25593637</pub-id></mixed-citation></ref><ref id="b110"><label>[110]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Benesch</surname><given-names>MG</given-names></name><name><surname>Brindley</surname><given-names>DN</given-names></name></person-group>
<article-title>Lipid phosphate phosphatases and their roles in mammalian physiology and pathology[J].</article-title>
<source><italic>J Lipid Res</italic></source>, <year>2015</year>
<pub-id pub-id-type="doi">10.1194/jlr.R058362</pub-id>.</mixed-citation></ref><ref id="b111"><label>[111]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomsig</surname><given-names>JL</given-names></name><name><surname>Snyder</surname><given-names>AH</given-names></name><name><surname>Berdyshev</surname><given-names>EV</given-names></name><etal/></person-group>
<article-title>Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo[J].</article-title>
<source><italic>Biochem J</italic></source>, <year>2009</year>, <volume>419</volume>(<issue>3</issue>): <fpage>611</fpage>-<lpage>618</lpage>.<pub-id pub-id-type="pmid">19215222</pub-id></mixed-citation></ref><ref id="b112"><label>[112]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barila</surname><given-names>D</given-names></name><name><surname>Plateroti</surname><given-names>M</given-names></name><name><surname>Nobili</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>The Dri 42 gene, whose expression is up-regulated during epithelial differentiation, encodes a novel endoplasmic reticulum resident transmembrane protein[J].</article-title>
<source><italic>J Biol Chem</italic></source>, <year>1996</year>, <volume>271</volume>(<issue>47</issue>): <fpage>29928</fpage>-<lpage>29936</lpage>.<pub-id pub-id-type="pmid">8939937</pub-id></mixed-citation></ref><ref id="b113"><label>[113]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kai</surname><given-names>M</given-names></name><name><surname>Wada</surname><given-names>I</given-names></name><name><surname>Imai</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Cloning and characterization of two human isozymes of Mg2+-independent phosphatidic acid phosphatase[J].</article-title>
<source><italic>J Biol Chem</italic></source>, <year>1997</year>, <volume>272</volume>(<issue>39</issue>): <fpage>24572</fpage>-<lpage>24578</lpage>.<pub-id pub-id-type="pmid">9305923</pub-id></mixed-citation></ref><ref id="b114"><label>[114]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pyne</surname><given-names>S</given-names></name><name><surname>Kong</surname><given-names>KC</given-names></name><name><surname>Darroch</surname><given-names>PI</given-names></name></person-group>
<article-title>Lysophosphatidic acid and sphingosine 1-phosphate biology: the role of lipid phosphate phosphatases[J].</article-title>
<source><italic>Semin Cell Dev Biol</italic></source>, <year>2004</year>, <volume>15</volume>(<issue>5</issue>): <fpage>491</fpage>-<lpage>501</lpage>.<pub-id pub-id-type="pmid">15271294</pub-id></mixed-citation></ref><ref id="b115"><label>[115]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pilquil</surname><given-names>C</given-names></name><name><surname>Dewald</surname><given-names>J</given-names></name><name><surname>Cherney</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Lipid phosphate phosphatase-1 regulates lysophosphatidate-induced fibroblast migration by controlling phospholipase D2-dependent phosphatidate generation[J].</article-title>
<source><italic>J Biol Chem</italic></source>, <year>2006</year>, <volume>281</volume>(<issue>50</issue>): <fpage>38418</fpage>-<lpage>38429</lpage>.<pub-id pub-id-type="pmid">17057224</pub-id></mixed-citation></ref><ref id="b116"><label>[116]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Benesch</surname><given-names>MG</given-names></name><name><surname>Dewald</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Lipid phosphate phosphatase-1 expression in cancer cells attenuates tumor growth and metastasis in mice[J].</article-title>
<source><italic>J Lipid Res</italic></source>, <year>2014</year>, <volume>55</volume>(<issue>11</issue>): <fpage>2389</fpage>-<lpage>2400</lpage>.<pub-id pub-id-type="pmid">25210149</pub-id></mixed-citation></ref><ref id="b117"><label>[117]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanyi</surname><given-names>JL</given-names></name><name><surname>Hasegawa</surname><given-names>Y</given-names></name><name><surname>Lapushin</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer[J].</article-title>
<source><italic>Clin Cancer Res</italic></source>, <year>2003</year>, <volume>9</volume>(<issue>10 Pt 1</issue>): <fpage>3534</fpage>-<lpage>3545</lpage>.<pub-id pub-id-type="pmid">14506139</pub-id></mixed-citation></ref><ref id="b118"><label>[118]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanyi</surname><given-names>JL</given-names></name><name><surname>Morris</surname><given-names>AJ</given-names></name><name><surname>Wolf</surname><given-names>JK</given-names></name><etal/></person-group>
<article-title>The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer[J].</article-title>
<source><italic>Cancer Res</italic></source>, <year>2003</year>, <volume>63</volume>(<issue>5</issue>): <fpage>1073</fpage>-<lpage>1082</lpage>.<pub-id pub-id-type="pmid">12615725</pub-id></mixed-citation></ref><ref id="b119"><label>[119]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>I</given-names></name><name><surname>Humtsoe</surname><given-names>JO</given-names></name><name><surname>Kohler</surname><given-names>EE</given-names></name><etal/></person-group>
<article-title>Lipid phosphate phosphatase-3 regulates tumor growth via beta-catenin and CYCLIN-D1 signaling[J].</article-title>
<source><italic>Mol Cancer</italic></source>, <year>2011</year>, <volume>10</volume>(<issue>1</issue>): <fpage>51</fpage>.<pub-id pub-id-type="pmid">21569306</pub-id></mixed-citation></ref><ref id="b120"><label>[120]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>J</given-names></name><name><surname>Raines</surname><given-names>TA</given-names></name><name><surname>Lynch</surname><given-names>KR</given-names></name><etal/></person-group>
<article-title>Decreased peritoneal ovarian cancer growth in mice lacking expression of lipid phosphate phosphohydrolase 1[J].</article-title>
<source><italic>PLoS One</italic></source>, <year>2015</year>, <volume>10</volume>(<issue>3</issue>): <fpage>e0120071</fpage>.<pub-id pub-id-type="pmid">25769037</pub-id></mixed-citation></ref><ref id="b121"><label>[121]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>KE</given-names></name><name><surname>Schang</surname><given-names>LM</given-names></name><name><surname>Brindley</surname><given-names>DN</given-names></name></person-group>
<article-title>Lipid phosphate phosphatase-2 activity regulates S-phase entry of the cell cycle in Rat2 fibroblasts[J].</article-title>
<source><italic>J Biol Chem</italic></source>, <year>2006</year>, <volume>281</volume>(<issue>14</issue>): <fpage>9297</fpage>-<lpage>9306</lpage>.<pub-id pub-id-type="pmid">16467304</pub-id></mixed-citation></ref><ref id="b122"><label>[122]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flanagan</surname><given-names>JM</given-names></name><name><surname>Funes</surname><given-names>JM</given-names></name><name><surname>Henderson</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets[J].</article-title>
<source><italic>Mol Cancer Ther</italic></source>, <year>2009</year>, <volume>8</volume>(<issue>1</issue>): <fpage>249</fpage>-<lpage>260</lpage>.<pub-id pub-id-type="pmid">19139135</pub-id></mixed-citation></ref><ref id="b123"><label>[123]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brindley</surname><given-names>DN</given-names></name><name><surname>Pilquil</surname><given-names>C</given-names></name></person-group>
<article-title>Lipid phosphate phosphatases and signaling[J].</article-title>
<source><italic>J Lipid Res</italic></source>, <year>2009</year>, <volume>50</volume>
<issue>Suppl</issue>: <fpage>S225</fpage>-<lpage>230</lpage>.<pub-id pub-id-type="pmid">19066402</pub-id></mixed-citation></ref><ref id="b124"><label>[124]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>A</given-names></name><name><surname>Wurch</surname><given-names>T</given-names></name><name><surname>Bailly</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Strategies and challenges for the next generation of therapeutic antibodies[J].</article-title>
<source><italic>Nat Rev Immunol</italic></source>, <year>2010</year>, <volume>10</volume>(<issue>5</issue>): <fpage>345</fpage>-<lpage>352</lpage>.<pub-id pub-id-type="pmid">20414207</pub-id></mixed-citation></ref><ref id="b125"><label>[125]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleming</surname><given-names>JK</given-names></name><name><surname>Wojciak</surname><given-names>JM</given-names></name><name><surname>Campbell</surname><given-names>M-A</given-names></name><etal/></person-group>
<article-title>Biochemical and Structural Characterization of Lysophosphatidic Acid Binding by a Humanized Monoclonal Antibody[J].</article-title>
<source><italic>J Mol Biol</italic></source>, <year>2011</year>, <volume>408</volume>(<issue>3</issue>): <fpage>462</fpage>-<lpage>476</lpage>.<pub-id pub-id-type="pmid">21392506</pub-id></mixed-citation></ref><ref id="b126"><label>[126]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldshmit</surname><given-names>Y</given-names></name><name><surname>Matteo</surname><given-names>R</given-names></name><name><surname>Sztal</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Blockage of Lysophosphatidic Acid Signaling Improves Spinal Cord Injury Outcomes[J].</article-title>
<source><italic>The American Journal of Pathology</italic></source>, <year>2012</year>, <volume>181</volume>(<issue>3</issue>): <fpage>978</fpage>-<lpage>992</lpage>.<pub-id pub-id-type="pmid">22819724</pub-id></mixed-citation></ref><ref id="b127"><label>[127]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crack</surname><given-names>PJ</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Morganti-Kossmann</surname><given-names>MC</given-names></name><etal/></person-group>
<article-title>Antilysophosphatidic acid antibodies improve traumatic brain injury outcomes[J].</article-title>
<source><italic>J Neuroinflammation</italic></source>, <year>2014</year>, <volume>11</volume>: <fpage>37</fpage>.<pub-id pub-id-type="pmid">24576351</pub-id></mixed-citation></ref><ref id="b128"><label>[128]</label><mixed-citation publication-type="webpage"><collab>ClinicalTrials.gov</collab>. <article-title>A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Lpathomab in Subjects With Neuropathic Pain[J]</article-title>
<year>2015</year>, <comment><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/show/NCT02341508">https://clinicaltrials.gov/show/NCT02341508</ext-link></comment>.</mixed-citation></ref><ref id="b129"><label>[129]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rancoule</surname><given-names>C</given-names></name><name><surname>Pradere</surname><given-names>JP</given-names></name><name><surname>Gonzalez</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Lysophosphatidic acid-1-receptor targeting agents for fibrosis[J].</article-title>
<source><italic>Expert Opin Investig Drugs</italic></source>, <year>2011</year>, <volume>20</volume>(<issue>5</issue>): <fpage>657</fpage>-<lpage>667</lpage>.</mixed-citation></ref><ref id="b130"><label>[130]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gross</surname><given-names>TJ</given-names></name><name><surname>Hunninghake</surname><given-names>GW</given-names></name></person-group>
<article-title>Idiopathic Pulmonary Fibrosis[J].</article-title>
<source><italic>N Engl J Med</italic></source>, <year>2001</year>, <volume>345</volume>(<issue>7</issue>): <fpage>517</fpage>-<lpage>525</lpage>.<pub-id pub-id-type="pmid">11519507</pub-id></mixed-citation></ref><ref id="b131"><label>[131]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>N</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Lysophosphatidic acid accelerates lung fibrosis by inducing differentiation of mesenchymal stem cells into myofibroblasts[J].</article-title>
<source><italic>J Cell Mol Med</italic></source>, <year>2014</year>, <volume>18</volume>(<issue>1</issue>): <fpage>156</fpage>-<lpage>169</lpage>.<pub-id pub-id-type="pmid">24251962</pub-id></mixed-citation></ref><ref id="b132"><label>[132]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swaney</surname><given-names>JS</given-names></name><name><surname>Chapman</surname><given-names>C</given-names></name><name><surname>Correa</surname><given-names>LD</given-names></name><etal/></person-group>
<article-title>A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model[J].</article-title>
<source><italic>Br J Pharmacol</italic></source>, <year>2010</year>, <volume>160</volume>(<issue>7</issue>): <fpage>1699</fpage>-<lpage>1713</lpage>.<pub-id pub-id-type="pmid">20649573</pub-id></mixed-citation></ref><ref id="b133"><label>[133]</label><mixed-citation publication-type="webpage"><collab>ClinicalTrials.gov</collab>. <article-title>Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis[J]</article-title>
<year>2015</year>, <comment><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01766817">https://clinicaltrials.gov/ct2/show/NCT01766817</ext-link></comment>.</mixed-citation></ref><ref id="b134"><label>[134]</label><mixed-citation publication-type="patent"><person-group person-group-type="author"><name><surname>Bradford</surname><given-names>WZ.</given-names></name></person-group>
<article-title>Pirfenidone and anti-fibrotic therapy in selected patients [J]</article-title>, <year>2012</year>: <patent>Patent (WO2012162592)</patent>.</mixed-citation></ref><ref id="b135"><label>[135]</label><mixed-citation publication-type="webpage"><collab>ClinicalTrials.gov</collab>. <article-title>Proof of Biological Activity of SAR100842 in Systemic Sclerosis[J]</article-title>
<year>2014</year>, <comment><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01651143">https://clinicaltrials.gov/ct2/show/NCT01651143</ext-link></comment>.</mixed-citation></ref><ref id="b136"><label>[136]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pattanaik</surname><given-names>D</given-names></name><name><surname>Postlethwaite</surname><given-names>AE</given-names></name></person-group>
<article-title>A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis[J].</article-title>
<source><italic>Discov Med</italic></source>, <year>2010</year>, <volume>10</volume>(<issue>51</issue>): <fpage>161</fpage>-<lpage>167</lpage>.<pub-id pub-id-type="pmid">20807477</pub-id></mixed-citation></ref><ref id="b137"><label>[137]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokumura</surname><given-names>A</given-names></name><name><surname>Carbone</surname><given-names>LD</given-names></name><name><surname>Yoshioka</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis[J].</article-title>
<source><italic>Int J Med Sci</italic></source>, <year>2009</year>, <volume>6</volume>(<issue>4</issue>): <fpage>168</fpage>-<lpage>176</lpage>.<pub-id pub-id-type="pmid">19521548</pub-id></mixed-citation></ref><ref id="b138"><label>[138]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castelino</surname><given-names>FV</given-names></name><name><surname>Seiders</surname><given-names>J</given-names></name><name><surname>Bain</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma[J].</article-title>
<source><italic>Arthritis Rheum</italic></source>, <year>2011</year>, <volume>63</volume>(<issue>5</issue>): <fpage>1405</fpage>-<lpage>1415</lpage>.<pub-id pub-id-type="pmid">21305523</pub-id></mixed-citation></ref><ref id="b139"><label>[139]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>A</given-names></name><name><surname>Furui</surname><given-names>T</given-names></name><name><surname>Tamaya</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>A gonadotropin-releasing hormone-responsive phosphatase hydrolyses lysophosphatidic acid within the plasma membrane of ovarian cancer cells[J].</article-title>
<source><italic>J Clin Endocrinol Metab</italic></source>, <year>2000</year>, <volume>85</volume>(<issue>9</issue>): <fpage>3370</fpage>-<lpage>3375</lpage>.<pub-id pub-id-type="pmid">10999836</pub-id></mixed-citation></ref><ref id="b140"><label>[140]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gierse</surname><given-names>J</given-names></name><name><surname>Thorarensen</surname><given-names>A</given-names></name><name><surname>Beltey</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation[J].</article-title>
<source><italic>J Pharmacol Exp Ther</italic></source>, <year>2010</year>, <volume>334</volume>(<issue>1</issue>): <fpage>310</fpage>-<lpage>317</lpage>.<pub-id pub-id-type="pmid">20392816</pub-id></mixed-citation></ref><ref id="b141"><label>[141]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbayianni</surname><given-names>E</given-names></name><name><surname>Magrioti</surname><given-names>V</given-names></name><name><surname>Moutevelis-Minakakis</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Autotaxin inhibitors: a patent review[J].</article-title>
<source><italic>Expert Opin Ther Pat</italic></source>, <year>2013</year>, <volume>23</volume>(<issue>9</issue>): <fpage>1123</fpage>-<lpage>1132</lpage>.<pub-id pub-id-type="pmid">23641951</pub-id></mixed-citation></ref><ref id="b142"><label>[142]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albers</surname><given-names>HM</given-names></name><name><surname>Ovaa</surname><given-names>H</given-names></name></person-group>
<article-title>Chemical evolution of autotaxin inhibitors[J].</article-title>
<source><italic>Chem Rev</italic></source>, <year>2012</year>, <volume>112</volume>(<issue>5</issue>): <fpage>2593</fpage>-<lpage>2603</lpage>.<pub-id pub-id-type="pmid">22335786</pub-id></mixed-citation></ref><ref id="b143"><label>[143]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>North</surname><given-names>EJ</given-names></name><name><surname>Howard</surname><given-names>AL</given-names></name><name><surname>Wanjala</surname><given-names>IW</given-names></name><etal/></person-group>
<article-title>Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors[J].</article-title>
<source><italic>J Med Chem</italic></source>, <year>2010</year>, <volume>53</volume>(<issue>8</issue>): <fpage>3095</fpage>-<lpage>3105</lpage>.<pub-id pub-id-type="pmid">20349977</pub-id></mixed-citation></ref><ref id="b144"><label>[144]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teo</surname><given-names>K</given-names></name><name><surname>Brunton</surname><given-names>VG</given-names></name></person-group>
<article-title>The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer[J].</article-title>
<source><italic>Biochem J</italic></source>, <year>2014</year>, <volume>463</volume>(<issue>1</issue>): <fpage>157</fpage>-<lpage>165</lpage>.<pub-id pub-id-type="pmid">25195735</pub-id></mixed-citation></ref><ref id="b145"><label>[145]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhave</surname><given-names>SR</given-names></name><name><surname>Dadey</surname><given-names>DY</given-names></name><name><surname>Karvas</surname><given-names>RM</given-names></name><etal/></person-group>
<article-title>Autotaxin Inhibition with PF-8380 Enhances the Radiosensitivity of Human and Murine Glioblastoma Cell Lines[J].</article-title>
<source><italic>Front Oncol</italic></source>, <year>2013</year>, <volume>3</volume>(<issue>236</issue>): <fpage>00236</fpage>.</mixed-citation></ref><ref id="b146"><label>[146]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schleicher</surname><given-names>SM</given-names></name><name><surname>Thotala</surname><given-names>DK</given-names></name><name><surname>Linkous</surname><given-names>AG</given-names></name><etal/></person-group>
<article-title>Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature[J].</article-title>
<source><italic>PLoS One</italic></source>, <year>2011</year>, <volume>6</volume>(<issue>7</issue>): <fpage>e22182</fpage>.<pub-id pub-id-type="pmid">21799791</pub-id></mixed-citation></ref><ref id="b147"><label>[147]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saga</surname><given-names>H</given-names></name><name><surname>Ohhata</surname><given-names>A</given-names></name><name><surname>Hayashi</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension[J].</article-title>
<source><italic>PLoS One</italic></source>, <year>2014</year>, <volume>9</volume>(<issue>4</issue>): <fpage>e93230</fpage>.<pub-id pub-id-type="pmid">24747415</pub-id></mixed-citation></ref><ref id="b148"><label>[148]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatraman</surname><given-names>G</given-names></name><name><surname>Benesch</surname><given-names>MG</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: implications for cancer treatment[J].</article-title>
<source><italic>FASEB J</italic></source>, <year>2015</year>, <volume>29</volume>(<issue>3</issue>): <fpage>772</fpage>-<lpage>785</lpage>.<pub-id pub-id-type="pmid">25398768</pub-id></mixed-citation></ref><ref id="b149"><label>[149]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>XJ</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Villeneuve</surname><given-names>NF</given-names></name><etal/></person-group>
<article-title>Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2[J].</article-title>
<source><italic>Carcinogenesis</italic></source>, <year>2008</year>, <volume>29</volume>(<issue>6</issue>): <fpage>1235</fpage>-<lpage>1243</lpage>.<pub-id pub-id-type="pmid">18413364</pub-id></mixed-citation></ref><ref id="b150"><label>[150]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>L</given-names></name><name><surname>Prosser</surname><given-names>HC</given-names></name><name><surname>Tan</surname><given-names>JT</given-names></name><etal/></person-group>
<article-title>Murine model of wound healing[J].</article-title>
<source><italic>J Vis Exp</italic></source>, <year>2013</year>(<volume>75</volume>): <fpage>e50265</fpage>.<pub-id pub-id-type="pmid">23748713</pub-id></mixed-citation></ref><ref id="b151"><label>[151]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Uchida</surname><given-names>H</given-names></name><name><surname>Nagai</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Evidence for de novo synthesis of lysophosphatidic acid in the spinal cord through phospholipase A2 and autotaxin in nerve injury-induced neuropathic pain[J].</article-title>
<source><italic>J Pharmacol Exp Ther</italic></source>, <year>2010</year>, <volume>333</volume>(<issue>2</issue>): <fpage>540</fpage>-<lpage>546</lpage>.<pub-id pub-id-type="pmid">20123931</pub-id></mixed-citation></ref><ref id="b152"><label>[152]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas Hess</surname><given-names>C</given-names></name></person-group>
<article-title>Checklist for Factors Affecting Wound Healing[J].</article-title>
<source><italic>Advances in Skin &#x00026; Wound Care</italic></source>, <year>2011</year>, <volume>24</volume>(<issue>4</issue>): <fpage>192</fpage>
<comment>110.1097/1001.ASW.0000396300.0000304173.ec</comment>.<pub-id pub-id-type="pmid">21422844</pub-id></mixed-citation></ref></ref-list></back></article>